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‘Our future challenge remains to 
develop novel approaches in the 
treatment of infants with congenital 
diaphragmatic hernia, as well as the 
perfection of innovative strategies 
already existing through ongoing 
laboratory and clinical research.’ 
 
Michael S. Irish, 1996 
 
 iii
 
Perinatal Cardiac Function in Congenital Diaphragmatic Hernia  
 
 
 
AGRADECIMENTOS 
 
 Gabriel Garcia Marqués diz que todos nascemos e morremos sozinhos. Pelo 
contrário, concretizar uma Tese de Doutoramento não é, definitivamente, um acto 
solitário. Como tal, expresso o meu agradecimento a todos aqueles que me 
apoiaram, motivaram e ensinaram durante os últimos anos. A rotina não é 
entediante para um médico que tenta manter uma actividade constante entre o 
serviço hospitalar, o trabalho de investigação e a actividade docente. Pelo caminho, 
vão-se perdendo sorrisos e alegrias que, no imediato, nem sempre nos afiguram 
recompensadas. Por isso, o apoio de tutores, colegas e amigos, nas suas diversas 
vertentes, são pedra angular para quem opta por trilhos menos fáceis. Na 
concretização desta Tese de Doutoramento várias têm sido as pessoas com papel 
relevante. No Instituto de Ciências da Vida e da Saúde, bem como no Serviço de 
Cardiologia Pediátrica, o espírito de colaboração foi uma constante. Em 
consequência, expresso o meu agradecimento: 
 
À Professora Doutora Cecília Leão, Directora do Instituto de Ciências da Vida 
e da Saúde da Escola de Ciências da Saúde da Universidade do Minho, agradeço a 
possibilidade de ter realizado grande parte deste trabalho nesta instituição. A sua 
incansável dedicação ao instituto proporciona um ambiente científico estimulante.  
 
Ao Prof. Doutor Jorge Correia-Pinto, por me ter permitido participar num 
projecto de vanguarda, me ter em grande parte transmitido o que sei em Ciência e, 
essencialmente, por ter acreditado nas minhas capacidades. A sua iniciativa de 
constituir um Grupo de Investigação pioneira no País, as excepcionais aptidões 
intelectuais e cirúrgicas, a preparação teórica irrepreensível, a postura positiva como 
médico e cientista, todos estes factores constituem, para mim, referente pedagógico 
e científico. 
 
Ao Prof. Doutor José Carlos Areias, a quem devo respeito e admiração pela 
vastidão dos conhecimentos científicos, pela confiança e o empenho na minha 
formação, pela forma como me acolheu no Serviço de Cardiologia Pediátrica e por 
me ter apoiado no caminho que escolhi. O espírito crítico, o estímulo permanente na 
actividade clínica e de investigação, o seu exemplo, tornam-no destinatário de 
profunda gratidão  
 v
Maria João Ribeiro Leite Baptista 2007 
 
 vi
 
 À Prof. Doutora Hercilia Guimarães, ao Dr. Gustavo Rocha, bem como às 
Dr.ªs Fátima Clemente, Goreti Silva, Angelina Morais e Beatriz Guedes, do Serviço 
de Neonatologia do Hospital de S. João, pela colaboração nos protocolos clínicos, 
pela partilha de experiência, por tudo o que me ensinaram nos gratos anos que 
trabalhei no Serviço e por continuarem a acreditar que é possível melhorar os 
cuidados prestados às nossas crianças. 
 
 À Dr.ª Teresa Vaz e aos Drs. José Monterroso, Eduardo Dias da Silva, 
António Vieira, Jorge Moreira, pelo empenho na minha formação como Cardiologista 
Pediátrica, pelas provas de cuidado e amizade. 
 
 Aos meus colegas no ID8, Cristina Silva, Sílvia Gonzaga, Rute Moura, Marta 
Santos e Gustavo Melo Rocha, inequivocamente elementos fulcrais no Grupo de 
Investigação, pela excelente colaboração que têm prestado nas diferentes fases de 
grande parte dos protocolos que basearam esta Tese. Registo o seu bom-humor, a 
inexcedível capacidade de trabalho; agradeço a amizade e a salutar troca de ideias. 
 
O meu sincero agradecimento à minha família e aos meus amigos: a sua 
compreensão e carinho constituíram forte incentivo na concretização deste projecto. 
 
 Porque, em última análise, o que me motiva são os recém-nascidos, pais e 
profissionais de saúde, que tenho visto lutar pela vida em anos de prática clínica, a 
todos eles expresso o meu mais profundo respeito. 
 
 
Perinatal Cardiac Function in Congenital Diaphragmatic Hernia  
 
 
ABSTRACT 
Congenital diaphragmatic hernia (CDH) is a congenital condition with variable illness 
severity that usually requires complex and multidisciplinary care. The physiologic 
consequences of this defect may be mild and minimally symptomatic at birth, but 
almost half of CDH infants present with severe forms of the disease, with poor 
outcome and extremely high mortality, despite aggressive treatment even in 
experienced teams with sophisticated management protocols. Morbidity and mortality 
associated with CDH is largely dependent of lung hypoplasia and pulmonary 
hypertension (PH). Most severe CDH newborns clinically resemble infants in terminal 
heart failure, even in the absence of cardiac malformation. During the last decade 
several authors suggested the existence of heart hypoplasia and immaturity in CDH, 
as occurs in lung. From our initial works we defined that heart hypoplasia in the 
experimental rat model of CDH was related with nitrofen and occurs only in early 
phases of gestation. In addition, in that model, prenatal treatment with vitamin A 
partially prevents the diaphragmatic defect and lung hypoplasia but only interfere with 
the molecular effect of nitrofen in lung hypoplasia. The absence of heart hypoplasia 
did not preclude the existence of some degree of molecular heart immatury that 
hampers heart function in pressure overload conditions. We exhaustively 
investigated throughout gestation several molecular parameters of heart 
development and we didn’t find any molecular signs of myocardium immaturity in this 
experimental model of CDH, since the molecular parameters were similar in all 
studied groups (control, nitrofen and CDH groups). With these results, we exclude 
the hypothesis that heart hypoplasia or immature could be the missing link in CDH 
responsible for greater mortality. We hypothesize that heart failure in CDH infants 
might be caused essentially by cardiac overload secondary to severe PH. In the 
experimental model of nitrofen induced CDH we demonstrated genetic molecular 
expression of the cardiac overload markers B type natriuretic peptide, endothelin-1 
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and angiotensinogen throughout gestation and after birth. We found that although 
during gestation the cardiac expression of those markers was similar in CDH and 
control fetuses, after birth there are a significant increase in the expression of all 
studied markers in right ventricle (RV) in CDH group. Simultaneously, in a clinical 
study we demonstrated that CDH Human infants present echocardiographic 
evidence of heart function adaptation, systolic and diastolic, in both ventricles. The 
heart dysfunction was also demonstrated by the increase in plasmatic N-terminal-
pro- B type natriuretic peptide (NT-proBNP) level, an overload biochemical marker. 
Moreover, plasmatic levels of NT-proBNP had an excellent correlation with PH and 
seem to have prognostic value in CDH. Taking into account all these findings, we 
suggest a protocol to evaluate PH and heart function in CDH infants, based in 
echocardiographic and serical parameters. This protocol would be useful to establish 
prognosis, follow-up of the clinical evolution, support the decision to pulmonary 
vasodilators therapy, and will help in the decision of the moment to surgical repair of 
CDH infants. 
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RESUMO 
A Hérnia Diafragmática Congénita (HDC) é uma perturbação do desenvolvimento 
embrionário que pode afectar diferentes órgãos para além do diafragma e do 
pulmão, como o coração ou o rim, exigindo uma abordagem complexa e 
multidisciplinar. As consequências fisiológicas da doença podem ser variáveis, 
existindo formas muito leves e minimamente sintomáticas até quadros clínicos em 
que se associam múltiplas malformações incompatíveis com a vida. No entanto, 
cerca de metade dos recém-nascidos (RN) afectados apresentam-se com formas 
caracterizadas por hipoplasia pulmonar grave, com prognóstico reservado e 
mortalidade inaceitavelmente elevada, apesar da disponibilização de abordagens 
terapêuticas agressivas e sofisticadas, mesmo em centros de referência. 
Actualmente, considera-se que a morbilidade e a mortalidade associadas à HDC 
estão dependentes da gravidade da hipoplasia pulmonar e da hipertensão pulmonar 
(HTP) existentes. No entanto, a evolução dos RN afectados caracteriza-se por uma 
grande imprevisibilidade, com agravamentos clínicos sustentados que muitas vezes 
não respondem à terapêutica instituída. Da experiência acumulada no tratamento 
destes RN apercebemo-nos de que os doentes mais gravemente afectados 
apresentam uma instabilidade ventilatória e hemodinâmica semelhante à da 
insuficiência cardíaca terminal, mesmo na ausência de doença cardíaca estrutural. 
Durante a última década tem sido sugerida a existência de hipoplasia e/ou 
imaturidade cardíaca nestes doentes. Os estudos desenvolvidos pelo nosso grupo 
demonstraram que no modelo da HDC induzida experimentalmente pelo nitrofeno 
verifica-se hipoplasia cardíaca apenas causada pelo nitrofeno e em fases precoces 
do desenvolvimento fetal. Neste modelo demonstramos que o tratamento prenatal 
com vitamina A previne parcialmente a ocorrência de defeito diafragmático e 
melhora o crescimento pulmonar, interferindo apenas nos mecanismos moleculares 
relacionados com o nitrofeno. A inexistência de hipoplasia cardíaca no termo da 
gestação, não excluía algum grau de imaturidade que eventualmente 
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comprometesse a função cardíaca em situações de sobrecarga ventricular de 
pressão. Assim, realizámos um estudo exaustivo para avaliar a expressão de 
diversos parâmetros moleculares de desenvolvimento cardíaco, ao longo da 
gestação, e não encontrámos qualquer evidência molecular de imaturidade 
miocárdica, pelo que excluímos a hipótese de existir hipoplasia ou imaturidade 
cardíaca que contribuísse para a elevada mortalidade destes doentes, valorizando a 
importância da sobrecarga de pressão causada pela HTP na função ventricular. No 
modelo experimental da HDC, demonstrámos que a expressão génica de 
marcadores de sobrecarga ventricular (peptídeo natriurético do tipo B, endotelina 1 e 
angiotensinogénio) não sofria qualquer alteração durante a gestação, registando-se 
um significativo aumento da sua expressão ventricular direita após o nascimento no 
grupo HDC. Simultaneamente, num estudo clínico efectuado demonstrámos que RN 
Humanos com HDC apresentam evidência ecocardiográfica de adaptação da função 
cardíaca, sistólica e diastólica, em ambos os ventrículos. Esta disfunção foi também 
demonstrada pelo aumento do fragmento N terminal do peptideo natriurético tipo B 
(NT-proBNP), um marcador bioquímico de sobrecarga ventricular. Os níveis 
plasmáticos de NT-proBNP apresentam uma excelente correlação com a HTP e 
parecem ter interesse prognóstico nos RN com HDC. Com base no trabalho 
desenvolvido propomos um protocolo de avaliação da HTP e da função cardíaca 
baseado em parâmetros ecocardiográficos e bioquímicos que possam monitorizar a 
evolução clínica, fundamentar a decisão de inicio de terapêutica vasodilatadora 
pulmonar, decidir o momento ideal para a cirurgia de reparação bem como 
estabelecer o prognóstico dos RN com HDC. 
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1. CLINICAL RELEVANCE OF CONGENITAL DIAPHRAGMATIC HERNIA 
 
Congenital diaphragmatic hernia (CDH) is a relatively infrequent condition (~1:2000 
births) with variable illness severity that usually requires complex and 
multidisciplinary care. This illness has been described as a developmental insult, with 
a simple anatomic defect in which a hole in the diaphragm allows abdominal viscera 
to herniate into the thorax. The physiologic consequences of this defect may be mild 
and minimally symptomatic at birth, but often they are severe. In our days, CDH is 
seen as a complex syndrome with frequent association with cromossomic anomalies 
and malformations, mainly cardiac, renal and skeletal. 
 
Almost half of CDH infants present with severe forms of the disease, predominantly 
with lung and diaphragmatic anomalies. These patients have poor outcome and 
extremely high mortality (~50%) despite aggressive treatment, even in experienced 
teams with sophisticated management protocols. Several authors believe that 
morbidity and mortality associated with CDH is largely dependent on lung hypoplasia 
and pulmonary hypertension (PH). Pulmonary hypoplasia installs during prenatal 
development and limited possibilities exist to attenuate it. PH is likely secondary to 
pulmonary hypoplasia and associated underdeveloped vascular bed, being for some 
authors the major determinant of postnatal clinical outcome.  
 
Regardless of experimental and clinical efforts using new modalities directed toward 
reduction of PH and/or improved pulmonary gas exchange in CDH infants, there has 
been relatively little impact on survival of the most severely affected subset of CDH 
infants. Antenatal therapies that promote lung growth before birth have been looked 
for, as an appealing approach for fetuses with severe CDH. However, fetal surgical 
intervention is invasive, technically demanding, and limited by the maternal and fetal 
risks. Less invasive approaches such as antenatal pharmacological treatment or 
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gene therapy to stimulate lung growth and maturation is being also considered. 
However, any of the above strategies had resulted in significant clinical impact. 
 
In our days, the postnatal therapy persists as the main approach in CDH. The 
diaphragmatic surgical repair is usually delayed until respiratory and hemodynamic 
stabilization and PH controlled. The medical management of these patients is 
designed to achieve an optimal oxygenation and is based in pulmonary vasodilators, 
high frequency ventilation, extracorporeal membrane oxygenation (ECMO) and 
surfactant administration. Nevertheless, the decision to start more aggressive 
therapy, like ECMO, and its monitorization, should be based in accurate parameters. 
In several centers, the evaluation of PH severity is considered the most important 
aspect in management of CDH infants. The assessment of pulmonary artery 
pressure is mainly based on clinical and echocardiographic estimation. However, 
echocardiographic evaluation is not always available and it is somewhat observer-
dependent and technically demanding in CDH infants due to the presence of 
abdominal organs in thoracic cavity. An easy and reliable method to assess PH 
remains to be defined and the identification of reliable prognostic parameters that can 
orient the clinical strategies is therefore warranted. 
 
According to this background, CDH persists as one of the main challenge in 
perinatology. It is imperative understand the basic mechanisms of the disease, in 
order to achieve a better clinical approach of affected infants. This justifies 
widespread deep and exhaustive investigation in this particular field of health 
sciences. This thesis reflects the work from our group and our attempts to clarify the 
hemodynamic aspects that could interfere in the outcome of CDH infants.  
 18
Perinatal Cardiac Function in Congenital Diaphragmatic Hernia  
 
2. HISTORICAL REVIEW  
 
If men could learn from history, what lessons it might teach us! 
Coleridge ST (1772-1834) 
 
The earliest recordings of diaphragmatic hernia comes from Hippocrates (460-370 
BC), indicated it being caused by traumatic perforations, usually with herniation of 
abdominal viscera into the thoracic cavity, 
and subsequent death [Coar, 1822]. 
Nevertheless, the first congenital 
diaphragmatic hernia was recorded only in 
1679 by Lazarus Riverius, as an incidental 
postmortem finding in a 24-year-old man 
[Riverius, 1679]. The first pediatric account 
of CDH was recorded in 1701 by Sir Charles 
Holt, who describes the clinical and 
postmortem findings of a two months old 
infant with CDH (Figure 1) [Holt, 1701]. 
 
In 1761, Morgagni described various types of 
diaphragmatic hernias, including the anterior 
diaphragmatic hernia which bears his name 
[Morgnani, 1769]. He further referred the small size of the ipsilateral lung, thus being 
the earliest account of pulmonary hypoplasia in association with CDH. In 1848, 
Bochdalek, whose name would became an eponym for CDH, described CDH 
occurring through both right and left posterolateral diaphragmatic defects 
[Bochkdalek, 1848]. 
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In 1888 Neumanm attempt the first CDH correction on a 19-year-old patient 
[Naumann, 1888] and in 1898 O’Dwyer performed the first abdominal approach for 
repair of CDH in a 3-year-old infant [Pilcher et al., 1890]. Both patients died. The first 
successful repair of CDH was reported only in 1902, by Heidenhain, in a 9 year-old-
boy [Heidenhain, 1905]. In 1925, Hebdolm reported 75% mortality in 44 congenital 
cases reviewed and suggested that early surgery of CDH might improve survival 
[Hedbolm, 1925]. The first successful repair of CDH in an infant was reported by 
Bettman and Hess in 1929 [Bettman & Hess, 1929]. Nevertheless, only in 1946 
Gross went on to report the first successful repair of a neonate less than 24 hours of 
age [Gross, 1946]. In contrast to this view of early operation, several authors have 
advocate and shown benefit to delayed surgical repair of CDH, after clinical 
stabilization. 
 
In the meantime, in the sequence of embryonic development investigation, Broman, 
in 1902, conclude that the absence of pleuro-peritoneal closure could result in 
diaphragmatic defect. In 1921 Korns recognized the importance of pulmonary 
hypoplasia in CDH and in 1953 Campanale and Rowland produced the first important 
paper extensively documenting the severe ipsilateral pulmonary hypoplasia, as well 
as degree of contralateral hypoplasia in CDH. In 1970, Murdock and Rowe 
demonstrated the role of acid-base and blood gas analysis in the determination of 
prognosis and therapy in CDH [Irish et al., 1996]. 
 
The introduction of the fetal lamb model of CDH by Lorimier and coworkers in 1967 
provided a reliable means for studying the pathophysiology of CDH [de Lorimier et 
al., 1967]. From 1990 to our days, the rat model of nitrofen induced CDH is the most 
used on experimental research due to easier manipulation and similarity with human 
disease [Tenbrick et al., 1990; Kluth et al., 1990]. Both models, which closely parallel 
the pathophysiologic consequences of CDH in humans, are used extensively to 
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advance our understanding of this condition. Furthermore, they had provided a mean 
of investigation and implementing several innovative strategies in the treatment of 
CDH.  
 
As our understanding of pulmonary hypoplasia and PH has evolved, CDH has 
become a physiologic emergency rather than a surgical one. The realization that 
early surgical repair was associated with unfavorable changes in lung compliance 
and gas exchange, resulted in the rationale for a period of preoperative stabilization 
and delayed surgery [Nair et al., 1983; Cartlidge et al., 1986; Charlton et al., 1991]. In 
our days, initial therapy is directed toward hemodynamic stabilization and respiratory 
support. This awareness results in improvement in therapeutics, like pulmonary 
vasodilators, sophisticated ventilatory strategies and ECMO [Nagaya et al., 1991; 
Reyes et al., 1998; Bartlett, 2005]. Prenatal diagnosis is possible from routine 
obstetric screening from 15 week’s gestation and several studies are currently 
evaluating the benefit of prenatal therapy, namely in utero surgery or genetic 
modulation of lung growth [Henriques-Coelho et al., 2004; Santos et al., 2006]. 
 
 
3. NORMAL AND CDH ABNORMAL EMBRYONIC AND FETAL DEVELOPMENT 
 
In the next sections, development of diaphragm, lung, heart and pulmonary 
vasculature will be briefly reviewed and focused in pathophysiologic aspects of CDH. 
 
3.1 Diaphragm development 
 
In Humans, the separation of the lateral plate of the intra-embryonic mesoderm occurs 
at the end of third week of gestation. This will determine the establishment of coelomic 
cavity, extending from the thoracic to the pelvic region. The most important structure 
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dividing the intra-embryonic coelomic cavity is formed by the septum transversum, a 
thick plate of mesodermal tissue occupying the space between the thoracic cavity and 
the stalk of the yolk sac (Figure 2). This septum does not separate the thoracic and 
abdominal cavities entirely, but leaves a large opening, the pericardioperitoneal canal, 
on each side of the foregut. 
 
According to the classical texts of embryology, the diaphragm derived from four 
distinct embryologic structures: i) the septum transversum, which forms the tendinous 
part of the diaphragm, ii) the two pleuroperitoneal membranes, iii) muscular 
components from the lateral and dorsal body walls, and iv) the mesentery of the 
esophagus, in which the crura of the diaphragm develop. Hence, diaphragmatic 
closure, determining the definite separation of the thoracic and abdominal portions of 
the coelomic cavity is determined by the pleuroperitoneal membrane, at the eight 
eek’s gestation [wells, 1954].  w
 
Examination of mouse models didn’t supported the hypothesis that diaphragmatic 
musculature is derived from the esophageal mesentery or ingrowth of muscle from 
the lateral body wall. The contribution of mesoderm to different regions of the 
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diaphragm seems to be essential, but not clearly determined. The somatic mesoderm 
may originate the pleuroperitoneal fold (PPF), a structure that will form the posterior 
diaphragm [Babiuk et al., 2003]. A sub-type of the somatic mesoderm, the septum 
transversum mesoderm, contributes to the anterior diaphragm [Babiuk et al., 2003; 
Liu et al., 2003; Yuan et al., 2003]. The PPF is a pyramid-shaped tissue that extends 
medially from the lateral cervical wall to the esophageal mesentery and fuses 
ventrally with the septum transversum (a distinct structure that will form the central 
ndon of the diaphragm). 
t 
ompletely understood.  
te
 
Several authors suggest that the embryogenesis of the PPF parallels that of the 
forelimb bud. Specifically, the substructure of the PPF is derived from mesenchymal 
cells migrating from the somatic mesoderm. Subsequently, muscle precursors 
migrating from the dermomyotome of cervical somites follow the guidance cues 
provided by the somatopleure substructure and become localized in the PPF. 
Afterwards, muscle and neuronal precursors migrate from the 3º, 4º and 5º cervical 
somites through PPF, leading to the formation of the muscular and neuronal 
components of the diaphragm, at the 4ª week’s gestation [Sze et al., 1995; Babiuk et 
al., 2003]. Growth and development of adjacent cells is probably dependent on 
growth factors secreted by the distal ends of PPF, but these mechanisms are still no
c
 
Additionally, the significance of mesenchyme in the formation of the membranous 
portion of the diaphragm has been re-enforced [Yuan et al., 2003]. Mice lacking the 
gene Slit3 (-/-) develop a central (septum transversum) CDH. Slit3 encodes a 
member of the Slit family of guidance molecules and is expressed predominantly in 
the mesothelium of the diaphragm during embryonic development. In Slit3 null mice, 
the central tendon region of the diaphragm fails to separate from liver tissue because 
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of abnormalities in morphogenesis. The CDH progresses through continuous growth 
er 
the right or left side at 14.5 days postconception (dpc), approximately 0.25 and 0.75 
cing evidence suggest that there being 
 common mechanism underlying the pathogenesis of CDH that targets primordial 
of the liver into the thoracic cavity.  
 
While the mechanisms underlying the etiology of CDH remain obscure, several 
theories pertaining to the pathogenesis of the condition have been proposed. The 
most commonly cited explanation for CDH states that there is an abnormality with the 
closure of the pleuroperitoneal canal. However, contrary to the often-documented 
theory, several data from animal models of CDH do not support this hypothesis. First, 
the diaphragm defects usually arise medially of the pleuroperitoneal canals, and the 
two can be spatially separated in these diaphragms. Secondly, nitrofen causes the 
formation of well-defined holes in the diaphragm which are clearly evident on eith
days prior to the closure of the right and left pleuroperitoneal canals, respectively. 
 
One inquisitive aspect in the CDH patophysiology is the presence of bilateral 
pulmonary hypoplasia from early stages of lung development. Based on this 
observation several authors suggested that the diaphragmatic defect in CDH could 
be secondary to lung hypoplasia, due to the absence of critical signals emanating 
from adjacent lung. Nevertheless, further studies established that the diaphragmatic 
defect is independent, as well as previous or simultaneous to the pulmonary 
hypoplasia. In fact, in Fgf10(-/-) null mutant mice, that do not develop lung tissue, 
Greer et al demonstrated that the diaphragm forms normally in the absence of any 
putative associated growth-related signals [Babiuk et al., 2002]. Thus the 
diaphragmatic defects associated with CDH are a primary defect and not a 
secondary result of lung malformation. Convin
a
diaphragm and lung development in parallel. 
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One of the most consistent hypothesis supports that defects can be traced back to 
much earlier stages of development during the formation of the primordial diaphragm 
and could be related to a defective PPF. Three-dimensional reconstructions of the 
PPF have demonstrated that the malformed areas in the animal model of CDH are 
consistently located in the dorsolateral region, the area affected in human CDH. The 
mesenchymal component of PPF seems to be defective, has suggested by data 
derived from studies in C-met (-/-) mice, demonstrating that diaphragmatic defects 
can be produced independently of myogenic process [Babiuk et al., 2002]. The C-
met protein, a receptor tyrosine kinase that is present on myogenic precursors, binds 
its ligand hepatocyte growth factor/scatter factor, signaling migration of these cells. 
Although the diaphragmatic musculature fails to form in the null mutants, the 
underlying connective tissue that comprises the amuscular substratum forms fully. 
These data provide a perspective on the mechanisms underlying CDH pathogenesis 
entirely novel from past theories. The focus now shifts from the muscularization of 
e diaphragm and closure of the pleuroperitoneal canals to understanding the 
Kablar et al., 1998], 
yogenin [Tseng et al., 2000], Pax3 [Li et al., 1999], RARa/RARb2 [Mendelsohn et 
th
mesenchymal amuscular component of the diaphragm. 
 
In fact, CDH is commonly considered as a developmental abnormality but its exact 
molecular mechanism is unknown. Correct muscularization of the diaphragm requires 
complex coordination of precursor cells to delaminate, migrate, target diaphragmatic 
tissue, and differentiate; mutations in several genes involved in those processes 
have already been shown to cause aberrant muscularization. Until now, studies in 
KO mices stresses the role of several genes in diaphragm muscularization such as 
C-met [Babiuk, 2002], Fog2 [Ackerman et al., 2005 ], Gab1 [Sachs et al., 2000], 
Gata4 [Jay et al., 2007], Lox [Hornstra et al., 2003], MyoD [
M
al., 1994], Slit3 [Liu et al., 2003] and wt1 [Clugston et al., 2006]. 
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Interestingly, Fog2 is the first gene recognized to be necessary for both primary lung 
development and primary diaphragm development providing evidence for the 
hypothesis that diaphragmatic defects may be associated with primary lung defects 
[Ackerman et al., 2005]. This highlights the hypothesis that an insult occurs in a 
ritical point of the embryonic development, affecting other organs than diaphragm, 
he heart.  
The development of the human lung encompasses a period starting with the 
 
 lung 
c
like the lung and even t
 
3.2 Lung development 
 
appearance of the tracheal outgrowth from the foregut and ending in early childhood.
 
The organogenesis of the lung can be divided into five distinct stages (Figure 3) [Post 
& Copland, 2002]. The early phases of human lung development comprises the 
embryonic (day 26 to 52 in human and 9.5 to 12 dpc in rat) and pseudoglandular 
(day 52 to end of 16 weeks of gestation and 13 to 17 dpc in rat) phases of
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development, after which a hierarchical pattern is apparent, the prospective 
conductive airways have been formed, and the acinar limits can be recognized. 
 
During the pseudoglandular phase the primitive airway epithelium starts to 
differentiate and neuroendocrine, ciliated and goblet cells appear. At this stage, 
mesenchymal cells have begun to form cartilage and smooth muscle cells. In 
humans, at 8 weeks, fetal breathing movements can be identified. In the subsequent 
canalicular phase (17 to 26 weeks in human and 18 to 19 dpc in rat), the airways 
branching pattern is completed and the gas-exchange region develop. During this 
period, respiratory bronchiole appears, interstitial tissue decreases, vascularization of 
peripheral mesenchyme increases, differentiation of the cuboidal epithelium into type 
I and type II cells occurs and begin the surfactant production. In the saccular 
(terminal sac) phase (24 to 36 week’s gestation in human and 20 to 22 dpc in rat), 
e growth of the pulmonary parenchyma, the thinning of the connective tissue 
ar stage (36 
eek’s gestation to term and at least 36 months postnatal in human and 20 to 22 dpc 
th
between airspaces, and the further maturation of the surfactant system are the most 
important steps towards ex-utero life. 
 
At birth, although already functional, the lung is structurally immature, because 
alveoli, the gas-exchange units of the adult lung, are practically missing. The 
airspaces present are smooth-walled transitory ducts and the saccules with primitive 
septa are thick and contain a double capillary network. During the alveol
w
in rat), alveoli are formed through a septation process that greatly increases the gas 
exchange surface area. 
 
Lung development is strictly regulated through reciprocal interactions between the 
epithelial and mesodermal mesenchymal layers, leading to the formation of the lung 
bud and branching morphogenesis, a reiterative process in which a network of 
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airways tubes is generated by the successive and invariant branching of the 
epithelium. When the embryo is approximately 4 weeks old, the primordium of the 
respiratory system appears as an outgrowth from the ventral wall of the foregut. 
During its separation from the foregut, the respiratory primordium forms a midline 
structure, the trachea, and two lateral outpocketings, the lung buds that progressively 
growth and branching in caudal and lateral directions. These processes are 
dependent on interactions between the foregut endoderm and its surrounding 
mesoderm. An interesting recent discovery links lung budding in foregut to cardiac 
development mesoderm. In fact, with regard to the lung localization in the foregut, the 
heart provides critical signals. Serls et al. found, using organ culture experiments, 
at lung specification is induced by adjacent cardiac mesoderm and the signals from th
this organ can be replaced with exogenous fibroblast growth factor (Fgf) 1 and 2 
[Serls et al., 2005]. 
 
Additionally, both lung budding and bronchial branching are dependent of retinoic 
acid (RA) signaling, which is ubiquiarious and maximal in endoderm, mesenchyme 
and primitive pleural tissues. Retinoic acid establishes a proximal type of cellular 
pattern, in which cells do not differentiate, keeping its potential to growth and 
branching. Further, the neighboring mesenchyme to the distal forming lung bud 
expresses Fgf10, essential for lung growth and branching. Fgf10 induces bud 
formation and the bud elongates following the nidus of Fgf10 as it migrates through 
the mesenchyme. Recent evidences suggest that Fgf10 promotes both the 
proliferation of the endoderm and its outward movement. The mitogenic effect of 
Fgf10 is antagonized by Bone Morphogenic Protein 4 (Bmp4) [Weaver et al., 2000]. 
As bud outgrowth continues endodermal, Bmp4 expressions increases. Meanwhile, 
Fgf10 expression gradually decreases at the tip but is upregulated laterally and 
overlies proximal endoderm, leading to the outgrowth of two new buds. The 
interaction between mesenchyme and epithelium allow a fine regulation of the lung 
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development, specifically of the differentiation and the proximal-distal growth (Figure 
4). Retinoic acid rule this local regulation, directly and indirectly thorough the Sonic 
hedgehog (Shh), inhibiting excessive expression of local fgf10 that could cause 
pulmonary immaturity [Malpel et al., 2000]. Ectopic branching between the branches 
is probably also quenched by TGF beta and extracellular matrix. Excess branching 
it 
Fgf 
and growth at the distal bud is downregulated by the induction of Sproutys to inhib
signaling [Warburton et al., 2000; Cardoso, 2001; Cardoso & Lü, 2006].  
 
Additionally, when lung branching, RA is also regulated and characterized by a 
proximal-distal gradient of RA activation, with less response in the distal 
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mesenchyme near sites of budding. This decreased response at distal sites can be 
ascribed to: i) diminished activity of RALDH-2 (retinaldehyde dehydrogenase), the 
major RA-synthesizing enzyme; ii) increased activity of COUP-FT2 (chicken 
ovoalbumin upstream promoter-Transcription Factor), responsible for inhibition of RA 
receptor; iii) increased RA degradation in the epithelium via P450RAI-mediated 
metabolism, an RA-inducible RA metabolizing enzyme of the cytochrome P450 
family. During normal development, restriction of RA signaling in time and space is 
ndamental for correct expression of Fgf10 and Bmp4 and distal morphogenesis. fu
Additionally, the RA gradient is critical for proximal-distal pattern formation [Wang et 
al., 2006].  
 
Pulmonary hypoplasia associated with CDH remains a major therapeutic problem. In 
CDH, a number of studies have investigated the underlying defect in these lungs. 
Gross congenital abnormalities of the lung are also seen [Nose et al., 2000]. Using 
morphometric analysis, in 1951, Reid found that the airway number, and thus 
alveolar, acinar, and arterial number, were all reduced in both lungs. This defect was 
most obvious in the lung ipsilateral to the CDH [Reid, 1951]. A defect in the 
regulation of branching morphogenesis could occur at any stage to yield such a 
phenotype. Thus one could postulate defects in RA, Shh, and Fgf signaling among 
others. Indeed CDH has been identified in several models where these pathways 
have been altered, and the RA pathway has been deeply studied. Retinoid signaling 
has been implicated in CDH pathogenesis in animals and Humans. Congenital 
diaphragmatic hernia and lung hypoplasia has been described in vitamin A deficiency 
models in rats, retinoic acid receptor (RAR) alpha/beta compound knockouts, as well 
as in mice with the deletion of the retinoic acid receptor X (RXR) ligand activation 
domain [Wilson et al., 1953; Mendelsohn et al., 1994; Antipatis et al., 1998; Mascrez 
et al., 1998; Kling et al., 2007]. In Human infants with CDH and lung hypoplasia, it 
was reported low plasma concentrations of retinol and retinol binding proteins and it 
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is account an association with chromosome 15q defects [Major et al., 1998; Enns et 
al., 1998]. A gene on chromosome 15 in the region of the deletion or translocation 
(15q24-26) encodes for cellular retinoic acid binding protein-1. Additionally, 
xogenous administration of vitamin A and RA decreases the incidence of CDH and 
 lungs relates with its ability 
 grow, at least in vitro, at higher rates than normal lungs. In this phenomenon 
sential component of CDH. Indeed by understanding the 
ctors that regulate lung and diaphragm formation and the interaction between both 
evelopment, we will obtain new insights into this important 
ongenital malformation. 
 
e
improves lung growth in the experimental model of CDH [Thébaud et al., 1999; 
Babiuk et al., 2004; Montedonico et al., 2006].  
 
To explain the pathogenesis of pulmonary hypoplasia in CDH Keijer et al. postulated 
the dual-hit hypothesis, which explains pulmonary hypoplasia in CDH by two 
developmental insults. The first insult occurs early in gestation, before diaphragm 
closure, due to a still unidentified background of genetic and environmental factors. 
This insult affects both lungs during branching morphogenesis in a similar fashion. 
After defective development of the diaphragm, the second insult occurs due to the 
presence of abdominal organs in thoracic cavity and affects the ipsilateral lung only 
at a later stage of development [Keijer et al., 2000]. In this scenario, herniated 
abdominal organs will interfere with fetal breathing movements of the ipsilateral lung, 
resulting in a greater impairment of the development of the ipsilateral lung than the 
contralateral lung. An interesting property of hypoplastic
to
seems to be involved cytokines like interleukin 6 and neuroendocrine products like 
ghrelin [Nogueira-Silva et al., 2006; Santos et al., 2006]. 
 
In conclusion, defects in early and late stages of lung development are likely to lead 
to lung hypoplasia, an es
fa
these structures during d
c
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3.4. Heart Development 
 
The development of the vertebrate heart can be considered an additive process, in 
which additional layers of complexity have been added throughout the evolution of a 
simple structure (linear heart tube) in the form of modular elements (atria, ventricles, 
septa, and valves). In mammals, cardiac progenitors cells arise from endoderm 
associated splanchnic mesoderm and coalesce at the anterior of the embryo. These 
cells adopt a crescent shape with the apex of the crescent lying close to the anterior 
junction between embryonic and extra-embryonic tissue, and the lateral arms of the 
crescent extending caudally. Cells of the cardiac crescent move ventrally and fuse or 
coalesce into a linear heart tube. This tube is composed of endothelial cells shrouded 
by a myocardial epithelium. The heartbeat is initiated at around this time and blood 
courses through the heart tube in a caudal to cranial direction; therefore, the venous 
flow of the heart is initially located caudally, and the arterial outflow tract cranially 
eart tube [Buckingham et al., 2005]. These cells contribute to the outflow 
in
[Dunwoodie, 2007].  
 
More recent tissue ablation, genetic ablation, and lineage labeling experiments in 
chick and mouse embryos have demonstrated the dynamic nature of heart tube 
formation, and the possible existence of two distinct heart fields [Buckingham et al., 
2005]. According to these models, cells of the first heart field form the cardiac 
crescent and begin to differentiate in situ. They undergo complex morphogenesis to 
form the primary heart tube. In mouse, the first heart field contributes largely to the 
future left ventricle (LV), forms parts of the atrioventricular canals as well as atria, 
and only has a small contribution to the future right ventricle (RV) [Zaffran et al., 
2004]. The second heart field is a population of undifferentiated myocardial 
progenitor cells that lies medial and caudal to cells of the crescent and, later, dorsal 
to the h
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tract, RV and parts of the LV and inflow region [Verzi et al., 2005; Zaffran et al., 
2004].  
 
The initiation of cardiac differentiation has been related with tinman gene in the fruit 
fly Drosophila melanogaster, and in vertebrates with the cardiac gene Nkx2-5. These 
genes encode an NK-class homeodomain-containing transcription factor and have 
important roles in the differentiation and morphogenesis of the early developing 
heart. In mice, Nkx2-5 is required for terminal differentiation of cardiac myocytes that 
includes, in large part, the establishment or maintenance of a ventricular gene 
expression program. Its role in early cardiac differentiation is crucial for the normal 
growth of the embryonic myocardium, which is apparent in the poorly developed 
myocardium of mice lacking Nkx2-5 and in the inability of this primitive cardiac 
structure to grow beyond the earliest stages of heart looping [Tanaka et al., 1998]. 
he gene expression of Nkx2-5 seems to be regulated by myocardin, a cardiac-
ools that coalesce to form the linear heart tube 
outsourakis et al., 1999]. In earlier step in the migration of cardiac precursors the 
T
specific transcription factor, a cardiac gene promoter via serum response factor-
binding sites [Wang et al., 2001].  
 
The progressive differentiation of precardiac cells appears to be regulated by the 
GATA family of zinc finger–containing transcription factors, and three GATA family 
genes have been identified as being expressed in the developing heart: gata4, gata5, 
and gata6 [Charron et al., 1999]. These genes are also important in the movements 
of the paired progenitor p
[K
basic helix-loop-helix (bHLH) transcription factor MesP1 has been shown to be 
required [Saga et al., 1999]. 
 
The heart tube grows by division of myocardial cells and by addition of cells to both 
poles of the heart [Buckingham et al., 2005]. During the looping stages of cardiac 
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morphogenesis, the outflow region swings to the right as the heart adopts a spiral 
form. With further development, the inflow portion of the heart, which includes the 
common atrium, moves in an anterior and dorsal direction such that the inflow and 
utflow complexes converge. The formation of the specialized chamber myocardium 
s are the precursors of the tricuspid and mitral valves, while in 
e outflow tract they form a scaffold for the aorticopulmonary septum which divides 
o
becomes evident during looping as it balloons out from the outer curvature of the 
heart tube in discrete zones [Christoffels et al., 2000].  
 
Considerable remodeling of the primitive heart occurs, beginning from the end of 
looping stages. The interventricular septum, which will divide the ventricles, forms in 
a highly defined region encompassing the junction of future LV and RV through 
polarized growth of myocardial cells [Franco et al., 2006]. The outer layers of the 
ventricles become highly proliferative, resulting in a thickening of the chamber walls 
to form the “compact layer”, important for building cardiac chamber mass and 
volume. Associated with non-chamber regions of the myocardium, endocardial 
cushions form, which initially act to direct independent patterns of blood flow for the 
pulmonary and systemic circuits [Moorman et al., 2006]. In the atrioventricular canal, 
endocardial cushion
th
the outflow tract into the aorta and pulmonary artery, and forms the aortic and 
pulmonary valves. 
 
Various promoter elements that restrict the expression of genes to the atrial or 
ventricular chambers have been identified. Iroquois homeobox gene 4 (Irx4) is a 
member of the Iroquois family of homeodomain-containing transcription factor genes. 
Expression of Irx4 is restricted at all stages of development to the ventricular 
myocardium in all species examined [Christoffels et al., 2000]. This gene is involved 
in the positive and negative regulation of chamber-specific myosin heavy chain gene 
expression in the ventricular myocardium. Irx4 represses the atrium-specific slow 
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myosin heavy chain 3 promoter acting via interaction with a retinoic acid receptor 
/vitamin D receptor complex of proteins [Wang et al., 2001]. Irx4-deficient mice have 
impaired cardiac function and develop cardiomyopathy. Another gene identified has 
regulator of ventricle-specific morphogenesis is the Hey2 gene, a ventricle-specific 
anscription factor related to the Hairy family of bHLH transcription factors 
ion, when it is restricted to 
e atria and LV [Bruneau et al., 1999]. Regarding, cardiac septation the multi-type 
tr
[Leimeister et al., 1999]. Mice lacking Hey2 develop a severe postnatal 
cardiomyopathy. 
 
The expression patterns and roles of the bHLH transcription factors dHand and 
eHand as well as the T-box transcription factor Tbx5 illustrate the correlation 
between chamber-restricted roles for factors expressed in a specific domain of the 
developing heart. dHand and eHand exhibit complementary patterns of expression in 
the developing mouse heart, with dHand more strongly expressed in the RV than in 
the LV and eHand predominantly restricted to the LV [Thomas et al., 1998]. 
Regarding Tbx5 it is expressed initially throughout the cardiac mesoderm in its 
earliest stages, but its expression pattern is rapidly refined, first as a posterior-
anterior gradient in the linear heart tube, until mid gestat
th
zinc finger transcription factor FOG-2 has been implicated as well retinoic acid 
receptors [Fosset et al., 2001; Mendelsohn et al., 1994].  
 
Maturation of the heart into fully functional trabeculated chambers and septation of 
the atria and ventricles from one another and between their left and right sides are 
important processes that require precise integration of growth and differentiation 
signals. Defects in these processes account for the majority of congenital heart 
malformations in humans, including atrial and ventricular septal defects (ASD and 
VSD, respectively), tetralogy of Fallot (TOF), common atrioventricular canal, and 
double-outlet right ventricle. Genetic analysis of inherited cardiac septation defects 
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has shown that dosage-sensitive redeployment or sustained function of transcription 
factors required for early cardiogenesis (eg, Nkx2-5 and Tbx5) is a major factor in 
septal morphogenesis. Dominant mutations in NKX2-5 have been found in patients 
with ASD, VSD, TOF, and Ebstein’s anomaly of the tricuspid valve, often 
ccompanied by conduction disease [Schott et al., 1998].  The identification of TBX5 
three distinct components: i) defective development of the cardiac outflow 
tract including persistent truncus arteriosus and outflow misalignment, ii) abnormal 
a
mutations in Holt-Oram syndrome has also provided insight into cardiac septation 
[Basson et al., 1999]. 
 
Neural crest is essential for cardiac development, due to its rule in development of: i) 
branchial arches e derived structures, including arch aortic arteries that will originate 
the great vessels in the thorax; ii) ventricular outflow tract and septum. Cardiac 
neural crest cells require a wide variety of environmental signals in order to be 
specified in the neural tube and then to migrate, proliferate, differentiate and survive. 
Wnt, FGF, BMP and RA, are required for neural crest induction. Many transcription 
factors and signaling molecules have been implicated in the later steps of migration, 
proliferation, survival and differentiation of the cardiac neural crest. Cardiac neural 
crest ablation leads to a number of cardiovascular and non-cardiovascular defects. 
Non-cardiovascular phenotypes include hypoplasia or aplasia of the thymus, 
parathyroids and occasionally the thyroid gland. The cardiovascular phenotypes 
include 
patterning of the great arteries, and iii) abnormal myocardial function [Hutson & Kirby, 
2007]. 
 
The association between CDH and congenital malformations is well defined by 
several authors, both in animal models [Migliaza et al. 1999] and in humans a wide 
spectrum of cardiovascular malformations associated with CDH been reported in the 
literature. These cardiac malformations are mainly truncoconal defects, as VSD, 
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TOF, truncus arteriosus, vascular rings and anomalies of ventricular outflow tract. In 
the animal model of CDH induced by the teratogen nitrofen, it is considered that 
nitrofen interferes with the normal neural crest cell migration, causing conutruncal 
heart malformations [Yu et al., 2002]. Interestingly, previous studies demonstrated in 
itro that nitrofen inhibits RALDH-2, the major retinoic acid-synthesizing enzyme that 
real significance were largely unknown 
nd not consensual. In previous studies, we demonstrated in the experimental rat 
 
LV 
which may be interpret f  
apparen ‘hypopla es and normal ve
v
has recently been shown to play an important role in lung and neural crest dependent 
heart development [Mey et al., 2003]. 
 
The prognostic value of heart morphology in CDH has been thorough studied. 
Several authors demonstrated that the presence of heart malformations significantly 
worsen the prognosis of the disease. Even in the absence of cardiac morphologic 
defects several authors suggests that the heart could be hypoplastic, as occurs in the 
lung, and this was suggested as a parameter of poor outcome in affected infants 
(Table 1). This heart underdevelopment should be secondary to LV hypoplasia 
[Siebert et al. 1984; Crawford et al., 1989; Schwartz et al., 1994; Thébaud et al., 
1997] and correlated with lung hypoplasia [Karamanoukian et al., 1995]. However, 
the determinants of heart hypoplasia and its 
a
model of CDH the absence of heart hypoplasia at term of gestation, specifically LV 
hypoplasia [Correia-Pinto et al. 2000, 2003].  
 
A possible explanation for these apparent contradictory data was recently purposed 
by Lin and colleagues. They consider that a slender compressed LV cavity is a 
common feature of congenital and acquired heart defects associated with pulmonary 
hypertensive vascular disease, deficient LV preload, or preferential RV volume
loading [Lin et al., 2007]. In these conditions, the enlarged RV compresses the 
ed as LV xamples o
sia’’ but normal aortic and mitral valv
 ‘‘hypoplasia’’. E other conditions with
t LV ‘ ntricular 
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Tabl stic of ar  in C
o
e 1. Progno  heart malformations and heart related p
Main Conclusi
ameters DH. 
Authors  n  Subject   Timing 
Kalache et al. 
2007 
Cardiac  axis  before  fetal  viability  has  no 
role in predicting postnatal outcome. 
Human  Early 
gestation 
Sokol et al. 
2006 
Antenatal  branch  PA  size  correlates with 
postmortem lung weight.  
Human  Fetal 
Graz  al.  Human   Newborn iano et
2005 
Congenital  heart  disease  (CHD)  is  with 
10.6% of CDH.  These  patients have poor 
survival compared to non CHD. 
Dil  
2004 
lon et al. PH  is a  critical determinant of  survival  in 
CDH.  Pulmonary  artery  pressure 
estimation predict clinical outcome. 
  Human  Newborn 
Verklan et al.  Human  Newborn 
2004 
Heart  rate  variability  as  an  indicator  of 
outcome in CDH. 
Cor al.  T  
gestation 
reia‐Pinto et 
2003 
Heart  growth  is  impaired  only  early  in 
gestation, due  to nonmechanical  factors. 
Heart weight predicts  lung weight only  in 
early gestational ages. 
Rat  hroughout
Cohen et al. 
2002 
Risk  of  death  is  higher  in  patients  with 
CDH plus CHD than without CHD. 
Human   Newborn 
Correia‐Pinto et al.  Rat  Term 
2000 
CDH  was  not  associated  with  heart 
underdevelopment. 
T  anabe et al.
2000 
Doppler  flow  patterns  through  ductus 
arteriosus  may  be  useful  for  predicting 
prognoses  and  selecting  suitable 
treatment for CDH infants. 
Human   Newborn 
Suda et al. 
2000 
A modified McGoon is the most significant 
prognostic factor in CDH. 
Human   Newborn 
Miggl  
 ni
iazza et al.
1999 
Heart hypoplasia occurs  in  the  rat model 
of CDH, but it is related with trofen. 
Rat  Term 
Baum t al.  Human   Newborn gart e
1998 
CDH  nonsurvivors  have  lower  LV  mass, 
low  LV  output  and  cardiac  malposition 
persisted despite CDH repair.  
Théb  al. 
1997 
aud et Fetal  LV  hypoplasia  (ventricular 
disproportion)  may  be  a  predictor  of 
outcome and of PH. 
Human  Fetal 
Karamanouki  al. an et
1996 
LV hypoplasia exist  in CDH and correlates 
with lung weight. 
Lamb  Fetal 
Schw  al. 
 may 
Human   Newborn artz et
1994 
LV mass index in CDH is significantly lower 
than  in other causes of PH. LV mass
predict need for ECMO. 
Shar  al. 
1992 
land et Under pment    left‐sided  he  
and cardiac malformations are prognostic 
factors in CDH. 
develo of art Human  Fetal 
M  in fetal CDH. omma et al. 
1992 
The heart is hypoplastic Rat  Fetal 
Crawford et al. 
1989 
Fetal  ventricular  disproportion  is 
associated with poor survival. 
Human  Fetal 
Siebert et al. 
1984 
LV hypoplasia in CDH.  Human   Newborn 
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volumes include total anomalous pulmonary venous drainage, atrioventricular canal 
defect, arteriovenous malformations, and almost any cause of severe PH. In CDH, it 
seems likely that apparent LV ‘‘hypoplasia’’, especially in the presence of a normal 
aortic and mitral valve, is due to compression of an under-filled pre-load deficient LV 
y the hypertensive RV rather than true LV hypoplasia. Indeed, LV mass, LV size, 
ference ratio may be 
etter predictors of mortality and morbidity than left ventricular volume [Cohen et al., 
of the left ventricle in CDH is more 
kely to be related to the state of the pulmonary vascular bed. 
b
aortic size, LV to RV ratio, and aortic to pulmonary artery discrepancy do not predict 
postnatal outcome in patients with CDH [Suda et al., 2000; Sokol et al., 2006]. 
 
In patients with CDH, it seems likely that severe lung hypoplasia and elevated 
pulmonary vascular resistance, which cause marked RV enlargement and the 
apparent left heart ‘‘hypoplasia’’ are the real modifiers of outcome. Indeed, indicators 
of lung hypoplasia such as branch pulmonary artery size, lack of branch pulmonary 
artery growth in utero, and postnatal lung area to head circum
b
2002; Sokol et al., 2006]. Thus, the morphology 
li
 
3.5 Development of pulmonary vascular system  
 
The blood vessels in the lung are thought to arise from a combination of 
angiogenesis and vasculogenesis. Angiogenesis is believed to contribute to the 
formation of the proximal or central blood vessels in the lung and occurs through 
several important steps: breakdown extracellular matrix, sprouting of cells from 
preexisting vasculature, survival and proliferation of these cells, migration of cells 
away from existing vessels, morphogenesis to form tubes, and recruitment of 
accessory cells. The term vasculogenesis is used to describe de novo creation of 
blood vessels, in this case out of the primordial pulmonary mesenchyme. Endothelial 
cells in the mesenchyme are thought to arise from primitive angioblasts. The end 
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result of vasculogenesis is a primitive plexus of endothelial cells that surrounds the 
branching epithelial tubes and then remodels to form mature arteries, capillaries and 
veins. In the classical description of pulmonary vascular development, these two 
as early as 38 days of gestation in 
umans and others that show markers of endothelial cells in a continuous fashion 
e airways and are thought to derive from direct 
ngiogenic budding off the aorta, much less is known about the specifics of bronchial 
nocyte activating 
olypeptide II (EMAP II), transforming growth factor-β (TGF-β) family, Wnt signaling 
processes merge at 10 to 11 weeks of gestation in humans in the form of 
communicating channels that provide continuity of blood flow [Stenmark et al., 2003].  
 
Some investigators challenge the theory of proximal angiogenesis and distal 
vasculogenesis, claiming that the proximal vasculature is also derived via 
vasculogenesis. Support for these claims include studies that demonstrate continuity 
between central and peripheral lung vessels 
h
from pulmonary arteries to the peripheral primitive vascular network, suggesting a 
common underlying process [Hal et al., 2000]. 
 
Another area of relative uncertainty concerns the bronchial arteries. Although these 
vessels are known to accompany th
a
arterial development and remodeling. Presently, the precise mechanisms of these 
processes remain to be elucidated. 
 
Critical molecular pathways determine the mechanisms of vascular development and 
could be altered in CDH disease. These determinants include transcription factors, 
peptide growth factors and receptors, cell adhesion receptors and intercellular 
adhesion molecules. Some of the most documented molecular mechanisms include 
vascular endothelial growth factor A (VEGF-A), endothelial mo
p
pathway, forkhead box, insulin-like growth factors (IGF-I and -II), Notch signaling, 
ephrins, as well as angiopoietins and Tie receptors [Miniati, 2007]. 
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As hypoxic environment is critical for vascularization, it is feasible that lung airway 
branching morphogenesis in utero is controlled by oxygen-regulated pulmonary 
vascular development. Recent reports have indeed suggested an active role for 
vascularization in lung development. In fact, epithelial branching morphogenesis in 
vitro was dramatically diminished when pulmonary vascular development was 
inhibited suggesting that vascular development might guide bronchial branching [van 
Tuyl et al., 2005]. Interestingly, a low-oxygen environment enhances branching of 
oth distal lung epithelium and vascular tissue and pulmonary vascular development 
emphasize the idea that smooth muscle cells 
ifferentiation delay might translate into a deficiency in contractile protein content, 
b
appears to be rate limiting for epithelial branching morphogenesis [van Tuyl et al.; 
2005]. 
 
Recently, our group detected that embryonic essential myosin light chain (MLC1a) 
and regulatory myosin light chain (MLC2) were absent in rat hypoplastic nitrofen-
induced fetal lungs during pseudoglandular stage of lung development. We also 
found that MLC1a was expressed only in vascular smooth muscle cells of pulmonary 
artery, whereas MLC2 was present in peri-bronchic smooth muscle cells and 
vascular smooth muscle cells of pulmonary vessels. MLC expression is most likely 
regulated by retinoic acid metabolism, whereas disruption of MLC1a expression 
during early pulmonary development led to growth and branching impairment, 
entailing an important role in normal lung branching morphogenesis [Santos et al., 
2007]. These observations 
d
which might have a role among the early molecular determinants of lung hypoplasia 
in CDH [Santos et al., 2007]. 
 
Further in utero development occurs according to the surrounding environmental 
stimuli and in preparation for postnatal respiration and gas exchange. The fetal 
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pulmonary vasculature is a low-flow, high-resistance system, with corresponding 
medial and adventitial hypertrophy of the blood vessels. During the first two months 
of life in normal human newborns, this vascular wall thickening gradually remodels in 
response to the change to a high-flow, low resistance system. Other changes that 
occur before birth include a rapid increase in the number of pulmonary blood vessels 
during the third trimester and a phenomenon known as “intussusceptive 
angiogenesis,” both of which account for the 30-fold expansion of the distal lung 
asculature surface area that occurs after birth. Intussusceptive angiogenesis refers 
cated on endothelial cells. In human fetal lung, KATP channels and ET-B 
ceptors could be important in mediating the perinatal pulmonary vasodilation 
v
to growth of the capillary network “within itself” and has now been described to occur 
in many vascular beds in addition to the lungs [Haworth et al., 2006]. 
 
Regarding pulmonary vessels tone, pulmonary expression of endothelial nitric oxide 
synthase (eNOS) increases throughout gestation, together with VEGF, and both 
factors are potent stimulants of pulmonary angiogenesis and vasorelaxation. In fetal 
lung, the concomitance of the increase in eNOS expression and the onset of 
alveolarization points to an important role of eNOS in airway maturation. The NO 
pathway is involved in angiogenesis, lung development, and vasorelaxation in human 
fetal lung. Despite this, during the perinatal period, when pulmonary vasodilation is 
maximal, endothelial NO synthase and VEGF are weakly expressed. This raises the 
possibility of the involvement of vasorelaxants other than NO at the time of birth. One 
candidate is endothelial-derived hyperpolarizing factor, which induces smooth muscle 
hyperpolarization by activating KATP channels. Another candidate is endothelin (ET)-
1, together with its receptors ET-A and ET-B. ET-A receptors are located exclusively 
on smooth muscle cells and mediate vasoconstriction, whereas ET-B receptors 
mediate vasoconstriction when located on smooth muscle cells and vasodilatation 
when lo
re
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crucial for adapting the pulmonary circulation to extrauterine life [Mohseni-Bod et al., 
2007]. 
 
At the time of birth, the pulmonary vasculature must dilate to accommodate the whole 
cardiac output. In CDH, this normal postnatal adaptation of the pulmonary 
vasculature does not happen. It seems that newborn pulmonary arteries continued to 
behave similar to the prenatal arterioles, i.e., they failed to respond to vasodilators, 
namely they exhibit a blocked NO-cGMP pathway [Vukcevic et al.; 2005]. In CDH 
occurs significant alteration in expression of ET-A receptors, VEGF and of KATP 
[Chang et al., 2004; Sakai et al., 2004; De Lagusie et al., 2005]. There are also 
reports of higher prevalence of the active polymorphisms of the angiotensinogen 
converting enzyme and angiotensinogen genes, abnormal response of the arterioles 
to hypoxia and to oxygen, abnormal distribution of matrix matalloproteinases and 
ssue inhibitors of metalloproteinases, as well as increase in the ratio of the 
ular and alveolar 
evelopment, thereby interfering with alveolarization and ultimately resulting in lung 
hypoplasia [Grover et al., 2005]. However, no previous work investigated this 
hypothesis neither the impact of PH in fetal heart function in CDH. 
 
ti
metabolites of thromboxane A2 to the metabolites of prostacycline [Nakayama et al., 
1992; Newell et al., 1998; Solari et al., 2004; Masumoto et al., 2006]. 
 
An interesting aspect is related with the possible existence of fetal PH in CDH. 
Grover et al. demonstrated experimentally that fetal PH impairs vascular growth, 
which disrupts critical signaling pathways regulating lung vasc
d
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4. ASSESSMENT OF PULMONARY HYPERTENSION 
 
4.1. Pulmonary hypertension in newborns 
 
The definition of pulmonary arterial hypertension in infants and children is the same 
as for adult patients. It is defined as a mean pulmonary artery pressure ≥25 mmHg at 
rest or ≥30 mmHg during exercise, with a normal pulmonary artery wedge pressure.  
 
Whether PH is due to increased flow or resistance depends on its cause. By 
definition, hyperkinetic PH refers to pulmonary arterial hypertension from congenital 
systemic to pulmonary communications with increased pulmonary blood flow, e.g. 
VSD or patent ductus arteriosus. Pulmonary venous hypertension is caused by 
disorders of left heart filling, e.g. mitral stenosis, pulmonary venous obstruction or LV 
failure. Unless exist left heart obstruction or dysfunction causing pulmonary venous 
hypertension, in PH the pulmonary arterial wedge pressure is normal.  
 
Persistent pulmonary hypertension of the newborn is a syndrome characterized by 
increased pulmonary vascular resistance, right–to-left shunting and severe 
hypoxemia. Persistent pulmonary hypertension of the newborn is frequently 
associated with pulmonary parenchymal abnormalities including meconium 
aspiration, pneumonia or sepsis, as well as occurring when there is pulmonary 
hypoplasia (as happen in CDH) or maladaptation of the pulmonary vascular bed in 
utero from unknown causes. In same instances there is no evidence of pulmonary 
parenchymal disease and the “injury” that is the trigger of the PH is unknown. 
Persistent pulmonary hypertension of the newborn is almost always transient, with 
infants either recovering completely without requiring chronic medical therapy or 
dying during the neonatal period despite maximal cardiopulmonary therapeutic 
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interventions. In contrast, patients with pulmonary arterial hypertension who respond 
to medical therapy appear to need treatment indefinitely.  
 
The evaluation of PH severity is considered important for management of PH in 
general as well as for CDH infants. The assessment of PH is crucial to decide upon 
pulmonary vasodilator therapy as well as to monitor its effects. Furthermore, in CDH 
infants, the decision for surgical repair should be based on evidence of PH 
stabilization [Downard et al., 2003]. However, since accurate evaluation of pulmonary 
artery pressure with Swan-Ganz catheter in newborns is not achievable, assessment 
of PH is mainly based on clinical and echocardiographic estimation, with its inherent 
limitations. Moreover, the establishment of more reliable parameters that could 
predict the PH severity and to screen early signs of PH-related heart dysfunction 
could particularly be useful to identify those newborns with more severe forms that 
could benefit from more aggressive treatment like ECMO. 
 
4.2. Clinical and echocardiographic assessment of PH and cardiac function  
 
Clinical assessment of PH in infants has some specificity because they have several 
intracardiac shunts. The right-to-left shunt at foramen ovale and ductus arteriosus 
indicate a severe PH. Thus, further hypoxia and PH manifests in infants by an 
increasing pre-to-post ductal gradient of Sat O2 >10%. This method although simple 
and useful as screening method of PH, it has poor ability to stratify the severity of 
PH. Additionally, in clinical practice, is frequent the evaluation of the severity of PH 
by the oxygenation and ventilator indices, that have been proposed has prognostic 
parameters in CDH [Skarsgard et al., 2005]. Nevertheless, these parameters could 
be dependent of others factors acting in gas exchange status. 
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In our days, most of the evaluation and monitorization of PH has being made with 
echocardiography, indirectly by assessment of RV repercussion of increased 
pulmonary vascular resistance. Noninvasive estimation of pulmonary artery systolic 
pressure (PASP) is important for the detection of PH in patients at risk, for monitoring 
the evolution of the disease, and to determine the effect of treatment. Several 
methods have been proposed to estimate pulmonary hemodynamic including PASP, 
diastolic pulmonary artery pressure (PAP), and mean PAP [Ullet et al., 2007]. The 
principal approach involves the measurement of the peak velocity of tricuspid 
regurgitation (TR) and the Bernoulli equation to estimate PASP. However, TR signal 
cannot be recorded in all patients. Therefore, alternative and easy applicable 
methods to estimate PAP would be very valuable in those cases when TR spectral 
envelope is faint or when there is no TR. Doppler echocardiography also allows 
estimation of diastolic PAP by means of measuring pulmonary regurgitation velocity 
and mean PAP using RV outflow tract flow acceleration time.  
 
The severity of PH could be indirectly evaluated by assessment of its repercussion in 
RV function, using echocardiography. Knowledge about the role of the RV in health 
and disease historically has lagged behind that of the LV. Less muscular, restricted in 
its role to pumping blood through a single organ, and less frequently involved in 
diseases of epidemic proportions such as myocardial ischemia, the RV has generally 
been considered a mere bystander, a victim of pathological processes affecting the 
cardiovascular system. Consequently, comparatively little attention has been devoted 
to how RV dysfunction may be best detected and measured, what specific molecular 
and cellular mechanisms contribute to maintenance or failure of normal RV function, 
how RV dysfunction evolves structurally and functionally, or what interventions might 
preserve RV function. Nevertheless, even the proportionately limited information 
related to RV function, its impairment in various disease states, like PH, and its 
impact on the outcome of those diseases, suggests that the RV is an important 
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contributor and that further understanding of these issues is of pivotal importance 
[Leite-Moreira, 1997; Correia-Pinto, 2003].  
 
The RV exposed to pressure overload, due to PH, has an initial adaptive response of 
myocardial hypertrophy followed by progressive contractile dysfunction. Chamber 
dilatation ensues to allow compensatory preload and maintain stroke volume despite 
reduced fractional shortening. As contractile weakening progresses, clinical evidence 
of decompensate RV failure occurs, characterized by rising filling pressures, diastolic 
dysfunction, and diminishing cardiac output, which is compounded by TR due to 
annular dilatation and poor leaflet coaptation. The increased size and pressure 
overload of the RV also produce diastolic dysfunction of the LV. Thus, the function 
and size of the RV are not only indicators of the severity and chronicity of PH but 
impose an additional cause of symptoms and reduced longevity. Right ventricular 
function is the most important determinant of mortality in patients with PH. The 
specific mechanisms underlying the development of RV failure secondary to PH are 
unclear. For example, it is uncertain whether some patients develop RV myocardial 
ischemia, whether there is microvascular endothelial cell dysfunction, and whether or 
not myocytes undergo apoptosis. In severe, end-stage PH, the shape of the RV is 
changed from the normal conformation and RV wall stress and free wall thickness 
appear to be inversely related.  
 
Implicit in the discussion of RV function and dysfunction is the notion that there are 
reliable means to its assessment. The measurement of RV function is difficult for 
many reasons, in part because of the interplay between intrinsic myocardial 
performance and RV loading conditions as well as due to the RV geometry. The 
development of load-independent markers of RV function is a worthwhile goal. In 
adults, several markers of RV dysfunction have been reported, with implications for 
clinical deterioration and mortality, in heart failure and PH, like RV ejection fraction, 
 47
Maria João Ribeiro Leite Baptista 2007 
 
RV dilatation, TR and Tei index [Tei et al., 1997; Grignola et al., 2006]. The extent to 
which any of these parameters are useful as outcome measures in clinical research 
or practice, namely in infants remains unclear. 
 
Recently, tissue Doppler imaging (TDI) emerge has an additional instrument to 
evaluate heart function. It is an extension of conventional Doppler flow 
echocardiography and has been proven to be a useful and feasible clinic et al tool for 
assessing global and regional LV and RV systolic and diastolic function since its 
introduction in the early 1990s. Also, it recently has emerged as a new method useful 
for predicting right atrial and ventricular pressure as well as evaluation of RV systolic 
and diastolic function [Nikitin et al., 2004]. Nevertheless, other objective observer-
independent methods are warranted to diagnose and stratify PH in infants. 
 
4.3. Biomarkers in Pulmonary Hypertension 
 
Several recent studies coming out mainly from non-pediatric centers have 
demonstrated the clinical relevance of biochemical markers to evaluate and 
determine the prognosis in patients with heart failure and PH. Several molecules 
which can be measured in the blood or sometimes in other biological fluids are 
known to be elevated in PH. These biomarkers are closely related to the 
physiopathology of PH, and two components must be emphasized: i) endothelium, 
which directly suffers the aggression that triggers several anomalies that ultimately 
lead to persistent vasoconstriction; ii) heart muscle, mainly the RV that suffer the 
pressure overload. Both endothelium and myocardium release on plasma several 
proteins that reflect the severity of the disease. The endothelium release proteins that 
result from the aggression process, and the myocardium releases proteins in an 
attempt to balance the hemodynamics impact of PH. From several of these markers, 
components of natriuretic system, ET-1, troponin, uric acid and endogenous NO 
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synthase inhibitor asymmetrical dimethylarginine (ADMA) seem to be the most 
promising molecules. 
 
B-type natriuretic peptide (BNP) is a hormone of predominantly ventricular origin 
produced and released in response to increased ventricular wall stress [Baugman et 
al., 2002]. NT-proBNP, the amino-terminal portion of the preprohormone, is secreted 
into the peripheral blood in equimolar portions to BNP, but it has a longer half-life and 
is easier to measure. In recent years, NT-proBNP has emerged as a very sensitive 
biochemical marker for ventricular dysfunction in adult heart failure, which plasmatic 
level could be used as a guide for the response to therapy and to predict prognosis 
[Bettencourt et al., 2005]. However, in children the knowledge about the significance 
of plasma levels of NT-proBNP is still limited. In healthy children, studies have shown 
that NT-proBNP levels are elevated soon after birth reaching its peak at 24 hours of 
life decreasing thereafter up to four months and remaining unchanged until the age of 
15 [Yoshibayashi et al., 1995; Fleming et al., 2001; Koch et al., 2003; Mir et al., 2003; 
Nir et al., 2004]. NT-proBNP levels are elevated in children with congenital heart 
disease or cardiomyopathy [Suda et al, 2003; Kunii et al., 2003; Westerlind et al., 
2004]. In infants, it was also demonstrated that NT-proBNP is elevated in 
symptomatic patent ductus arteriosus in preterms [Holmstrom et al., 2001, Choi et 
al., 2005] and PH [Reynolds et al., 2004].  
 
Endothelin-1 is a potent vasoconstrictor peptide derived from endothelial cells that is 
also produced by cardiac myocytes [Suzuki et al., 1993]. ET-1 induces myocardial 
cell hypertrophy and has a potent positive (ET-A receptors) and negative (ET-B 
receptors) inotropic and chronotropic effects on isolated heart muscle. The 
production of ET-1 in the heart is increased in pressure overload as in PH [Shah, 
2007]. 
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Cardiac troponin T is a specific cardiac troponin T (cTnT) and a marker of 
cardiomyocyte injury which is detectable when either the LV or the RV is injured. 
Torbicki and colleagues have recently evaluated the prognostic value of this 
biochemical parameter in adult patients with PH and found that despite similar 
cardiac hemodynamic, patients with higher levels of cTnT had worse survival 
[Torbicki et al., 2003]. It is therefore likely that cTnT is a marker of excessive stress to 
the RV, and the authors suggest that cTnT may be of use in making therapeutic 
decisions in adult’s patients. 
 
Uric acid may be elevated in the blood of patients with chronic hypoxic conditions 
such as heart failure or lung disease. The elevation is thought to be the consequence 
of impaired oxidative metabolism of the tissue, with increased degradation of adenine 
nucleotides such as ATP. Uric acid is known to be a risk factor for long term mortality 
in heart failure. Uric acid has been found to be elevated in the serum of patients with 
idiopathic PH, and correlates with pulmonary vascular resistance [Nagaya et al., 
1999]. 
 
Similarly, in adult settings, some researchers investigated the potential role of the 
ADMA in patients with idiopathic pulmonary arterial hypertension and concluded that 
increased ADMA plasma levels are associated with unfavorable pulmonary 
hemodynamic and worse outcome in patients with PH (Kielstein et al., 2005]. 
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AIMS  
 
This dissertation was planned aiming to unravel certain aspects of perinatal heart 
development and adaptation to CDH.  Thus, the specific aims of these studies are 
described bellow: 
 
i. Evaluate the effect of fetal treatment with vitamin A in lung growth of CDH 
fetuses, in the nitrofen rat model (study n.º 1). 
 
ii. Investigate the existence of cardiac immaturity in the experimental rat 
model of nitrofen induced CDH during perinatal development (study n.º 2). 
 
iii. Establish the normal perinatal genetic expression pattern of molecular 
ventricular overload markers and adaptations in CDH, in the experimental 
nitrofen induced rat model of CDH (study n.º 3). 
 
iv. In Human infants submitted to cardiac catheterization evaluate the 
correlation between NT-proBNP and RV pressure (study n.º 4). 
 
v. In Human CDH newborns, clarify the heart function adaptation to 
pulmonary hypertension and to ascertain the usefulness of ventricular 
overload biomarkers as prognostic indices (study n.º 5). 
 
vi. To contribute for the establishment of a novel perinatal cardiovascular 
assessment protocol to apply in infants with CDH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
EFFECT OF ANTENATAL TREATMENT WITH VITAMIN A ON PULMONARY GROWTH 
IN CONGENITAL DIAPHRAGMATIC HERNIA 
 
 
www.elsevier.com/locate/jpedsurgAntenatal vitamin A administration attenuates lung
hypoplasia by interfering with early instead of late
determinants of lung underdevelopment in congenital
diaphragmatic herniaMaria J. Baptistaa,c, Gustavo Melo-Rochaa, Carla Pedrosab, Sı´lvia Gonzagaa,
Anto´nia Telesb, Jose´ Esteva˜o-Costad, Jose´ C. Areiasb,c, Alan W. Flakee,
Adelino F. Leite-Moreirab, Jorge Correia-Pintoa,*aDevelopment Unit, Health and Life Research Institute, Health Sciences School, University of Minho,
4710-057 Braga, Portugal
bDepartment of Physiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
cDepartment of Pediatric Cardiology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
dDepartment of Pediatric Surgery, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
eDepartment of General Surgery, The Children’s Institute for Surgical Science,
The Children’s Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA0022-3468/05/4004-0009$30.00/0 D 200
doi:10.1016/j.jpedsurg.2005.01.034
This work was granted by FCT (PRA
T Corresponding author. Unidade de
Minho, 4710-057 Braga, Portugal. Tel.:
E-mail address: jcp@ecsaude.uminh
Index words:
Lung development;
Retinoic acid;
Nitrofen rat model;
CDHAbstract
Background/Purpose: Early and late lung underdevelopment in congenital diaphragmatic hernia
(CDH) is likely caused by nonmechanical (directly mediated by nitrofen) and mechanical (mediated
by thoracic herniation) factors, respectively. The authors investigated if vitamin A enhances lung
growth because of effects on both early and late determinants of lung hypoplasia.
Methods: Twenty-seven pregnant Wistar rats were exposed on embryonic day (E)9.5 to 100 mg of
nitrofen or just olive oil. From nitrofen-exposed pregnant rats, 12 were treated at day 9.5 or 18.5
with 15,000 IU of vitamin A. Lungs were harvested at E18, E20, and E22, weighed, and analyzed
for DNA and protein contents. Left and/or right lung hypoplasia was estimated by assessment of the
ratios of lung to body weight and left to right lung weight. Fetuses were assigned to 5 expe-
rimental groups: baseline (exposed neither to nitrofen nor vitamin A), nitrofen (exposed to nitro-
fen without CDH), CDH (exposed to nitrofen with CDH), nitr+vitA (exposed to nitrofen without
CDH and treated with vitamin A), and CDH+vitA (exposed to nitrofen with CDH and treated
with vitamin A).
Results: Incidence of hernia was significantly reduced in fetuses treated with vitamin A. When vitamin
A was administered at E9.5, the authors observed similar effect on lung hypoplasia measured throughJournal of Pediatric Surgery (2005) 40, 658–6655 Elsevier Inc. All rights reserved.
XIS/C/SAU/11301/98) through Unidade I&D Cardiovascular n851/94/FCT, Portugal.
Desenvolvimento, Instituto de Cieˆncias da Vida e da Sau´de (ICVS), Escola de Cieˆncias da Sau´de, Universidade do
+351 253 604 807; fax: +351 253 604 809.
o.pt (J. Correia-Pinto).
Vitamin A and lung development in CDH 659ratio of lung to body weight at E18 in the nitrofen and CDH groups (nitrofen 1.92% F 0.05%, CDH
1.92% F 0.04%), whereas lung hypoplasia was attenuated relative to baseline (2.45% F 0.05%) in 5%
and 4% in nitrofen (nitr+vitA 2.05% F 0.03%) and CDH (CDH+vitA 2.08% F 0.04%) groups,
respectively. At E20, lung hypoplasia was increased in CDH compared with nitrofen groups (nitrofen
2.52% F 0.1%, CDH 2.39% F 0.05%), whereas vitamin A attenuated lung hypoplasia, in relation to
baseline (3.20% F 0.07%), 14% in both nitrofen-exposed groups (nitr+vitA 2.96% F 0.03%,
CDH+vitA 2.83% F 0.03%). At E22, lung hypoplasia was significantly higher in CDH group than
nitrofen group (nitrofen 2.13% F 0.06%, CDH 1.48% F 0.03%), whereas lung hypoplasia was
attenuated in 9% of both nitrofen-exposed groups (nitr+vitA 2.35% F 0.06%, CDH+vitA 1.69% F
0.05%) in relation to baseline group (2.38% F 0.04%). Administration of vitamin A at E18.5 produced
no significant effects on lung growth.
Conclusions: The authors conclude from these results that antenatal administration of vitamin A
attenuates lung hypoplasia in CDH by interfering with early determinants of lung underdevelopment.
This finding may have clinical implications because prenatal diagnosis of human CDH commonly
occurs after 16 weeks’ gestation when late determinants of lung hypoplasia likely predominate.
D 2005 Elsevier Inc. All rights reserved.Despite improved understanding of the pathophysiology
of congenital diaphragmatic hernia (CDH) and advances in
perinatal care, morbidity and mortality remain significant
[1-3]. The leading causes of mortality in CDH are
pulmonary hypoplasia and severe persistent pulmonary
hypertension [2].
Regardless of experimental and clinical efforts using new
modalities directed toward reduction of pulmonary hyper-
tension and/or improved pulmonary gas exchange in CDH
infants [4-9], there has been relatively little impact on
survival of the most severely effected subset of CDH infants
[1,2]. Antenatal therapies that promote lung growth before
birth remain an appealing approach for fetuses with severe
CDH. Fetal surgical intervention is invasive, technically
demanding, and limited by the maternal and fetal risks
[10,11]. In fact, it was recently demonstrated, in a controlled
randomized trial, that tracheal occlusion did not improve
survival or morbidity rates in human fetuses with CDH,
when compared with standard postnatal care [12]. There-
fore, less invasive approaches such as antenatal pharmaco-
logical treatment to stimulate lung growth and maturation
have been considered [13-17].
Retinoids and retinoic acid are vitamin A compounds that
function as essential signals for growth and differentiation
during lung and diaphragmatic development through bind-
ing to its receptors: retinoic acid receptor (RAR) and
retinoid X receptor (RXR) [18-20]. Genetic analysis of the
function of the various RARs and RXRs, in the mouse fetal
lung, has been shown to have lung hypoplasia and/or
diaphragmatic defect [21-23]. In human beings, the expres-
sion of RXR occurs in both proximal (epithelia and
mesenchyme of the trachea and bronchi associated with
cartilage) and distal (epithelia and mesenchyme of smaller
distal bronchi) sites in fetal lung, whereas RAR is detected
in distal mesenchymal lung cells [24]. In addition, several
studies suggest that retinoids may have an important role in
the pathogenesis of CDH [21,25-27]. The´baud et al
demonstrated in the nitrofen rat model that early adminis-tration of a single dose of prenatal vitamin A increases
survival, decreases the incidence of CDH, and increases
lung growth in nitrofen-induced CDH [14].
In the nitrofen-induced rat model of CDH, it has been
previously demonstrated that lung hypoplasia, in contrast
to heart hypoplasia [28,29], has distinct early and late
gestational determinants. Early determinants appear to
be directly mediated by nitrofen [28,30,31] because
similar degrees of lung hypoplasia are observed at early
gestational time points with or without concomitant
CDH. Late determinants, likely because of mechanical
factors caused by thoracic herniation, only become mani-
fest after embryonic day (E)18 of gestation as we
have previously demonstrated [28]. In human beings,
prenatal diagnosis typically occurs relatively late in gesta-
tion (after 16 weeks) [32,33]. Analogy to the nitrofen-
induced model would imply that lung hypoplasia occurring
after prenatal diagnosis would be predominantly caused
by late determinants.
The purpose of the present study was therefore to clarify
if the ameliorating effects of antenatal vitamin A adminis-
tration occurred during the early or late determinants of lung
hypoplasia in CDH. This question would be of greatest
relevance in consideration of timing and efficacy of
antenatal treatment of human fetuses with vitamin A.1. Materials and Methods
1.1. Animal model
Wistar female rats (225 g, Charles River, Barcelona)
were maintained in appropriate cages under controlled
conditions and fed with commercial solid food. The rats
were mated and checked daily for introital plugging. The
day of plugging was defined as gestational day 0 for time
dating. Twenty-seven pregnant rats were treated at day
9.5 of gestation either with a dose of 100 mg of nitrofen
Fig. 1 Ratio of lung to body weight in baseline, nitrofen-exposed fetuses without CDH (nitrofen), nitrofen-exposed fetuses with CDH
(CDH), and vitamin A–treated groups (nitr+vitA and CDH+vitA). In all nitrofen-exposed fetuses, a significant reduction in ratio of lung to
body weight was observed compared with the baseline group at the same gestational time point. Early (E9.5) antenatal administration of
vitamin A enhanced lung growth in all studied groups (P b .05: *nitr+vitA vs nitrofen; wCDH+vitA vs CDH).
M.J. Baptista et al.660dissolved in 1 mL of olive oil administered by gavage or
with an equal volume of olive oil alone.
1.2. Vitamin A administration
The administration of vitamin A was performed in
12 time-dated pregnant rats treated with nitrofen. Two
different protocols were performed: in the first protocol,
vitamin A was administered at E9.5, whereas in the second
protocol, vitamin A was administered at E18.5. In both
protocols, vitamin A (15,000 IU; A-Vite, J Neves,
Portugal) was diluted in 1 mL of olive oil and given
through an oral gastric tube. The dose of vitamin A was
chosen according to Wilson et al [27] as within the
therapeutic range. Care was taken to avoid photo degrada-
tion of the vitamin A by ensuring that fresh vials of
vitamin A were used and that the oral gastric tube was
protected from light.
1.3. Experimental design
Pregnant rats treated with nitrofen alone or nitrofen and
early (E9.5) vitamin A were killed at E18, E20, and E22
(term gestation E22). Pregnant rats treated with vitamin A
late (E18.5) in gestation were killed only at E22.
From both protocols and at each time point, fetuses were
harvested by cesarean section, and the body weights were
measured on a precision balance (Scaltec Instruments,
SBC 21, Heeligeesdadt, Germany). Under binocular mi-
croscopy (Leica, Wild M651.MS-D, Herbrugg, Switzer-land) and after fetal decapitation, a laparotomy was
performed to inspect the diaphragm. Through a median
sternotomy, the lungs were excised, and the wet weights of
each lung were then measured. Fetuses where assigned to
5 experimental groups: baseline (exposed neither to nitrofen
nor vitamin A), nitrofen (exposed to nitrofen without CDH),
CDH (exposed to nitrofen with CDH), nitr+vitA (exposed
to nitrofen without CDH and treated with vitamin A), and
CDH+vitA (exposed to nitrofen with CDH and treated
with vitamin A).
1.4. Biochemical studies
Samples from left lung (LL) were weighed, snap frozen
in liquid nitrogen, and stored at 80 8C until processing for
determination of tissue protein and DNA. Protein content
was determined by using an array spectrophotometer (model
Jasco 7850 UV, Japan) with a modified micro-Lowry
method assay (Sigma-Aldrich, Mo, USA). Bovine serum
albumin (Sigma Chemical) was used as the standard. DNA
was extracted from each sample according to the recom-
mended protocol using the Quantum Prep Aqua Pure
Genomic DNA kit (Biorad, Calif, USA).
1.5. Measurements
Wet weights of both lungs were measured, and the
weights were expressed as a percentage of corresponding
fetal body weight. Total DNA and protein contents of the
LL were calculated and normalized for fetal body weight.
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Fig. 2 Effects of vitamin A (E9.5) on lung hypoplasia throughout gestation. Nitrofen and CDH groups show divergence in lung hypoplasia
as gestation proceeds. Whereas nitrofen-induced lung hypoplasia decreases as gestational age progresses, CDH-induced LL hypoplasia
increases. At each time point of gestation, prenatal administration of vitamin A ameliorated the lung hypoplasia to a similar extent in the
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Vitamin A and lung development in CDH 661For each gestational time point and experimental group,
lung hypoplasia was estimated using the following formula:
[(lung-to-body weight ratio)group  (mean lung-to-body
weight ratio)baseline]/(mean lung-to-body weight ratio)baseline
 100%. The ratio of left to right lung weight was
calculated for each fetus using the formula: (LL weight)/
(right lung weight).
1.6. Statistical analysis
All quantitative data are presented as mean values F SE.
The different data sets of baseline, nitrofen, CDH, nitr+vitA,
and CDH+vitA groups failed in the Kolmogorov-Smirnov
test for normality. Therefore, statistical analysis was
performed by the 2-way analysis of variance on ranks,
and the Dunn test for posttest analysis. Statistical signifi-
cance was set at P b .05.2. Results
A total of 439 rat fetuses, distributed through the
3 gestational time points, were analyzed: 114 in the baselineNitrofen
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Fig. 3 Left and right lung hypoplasia in nitrofen and CDH groups. In th
right and left lungs, even if the degree of such hypoplasia decreases at E
lungs at E18 and nonsignificantly different from the nitrofen group at
hypoplasia on left than on right lung, which is also significantly biggergroup, 153 exposed only to nitrofen, and 172 exposed to
nitrofen and vitamin A at E9.5. In addition, 24 nitrofen-
exposed rat fetuses treated with vitamin A at E18.5 were
analyzed at E22 and compared with nitrofen-exposed
fetuses at the same gestational time points.
2.1. Early (E9.5) administration of vitamin A
The incidence of hernia was significantly reduced in
fetuses treated with vitamin A (incidence of CDH: 50% in
nitrofen-exposed fetuses, 22% in nitrofen-exposed fetuses
treated with vitamin A).
Results from lung development are graphically repre-
sented in Fig. 1. At E18, the ratio of lung to body weight
was similar in both nitrofen-exposed groups, but signifi-
cantly lower than in the baseline group. Antenatal treatment
with vitamin A improved the ratio of lung to body weight in
both nitrofen-exposed fetuses. However, in comparison to
baseline group, treatment with vitamin A completely
ameliorated the reduction in ratio of lung to body weight
by similar percentage: 5% and 4% in the nitrofen and CDH
groups, respectively (Fig. 2).-50
-40
-30
-20
-10
0
CDH
E18 E20 E22
e nitrofen group, lung hypoplasia is similar throughout gestation in
22. In the CDH groups, lung hypoplasia is similar for right and left
this gestational age. From E20 on, CDH fetuses show a bigger
than in nitrofen group.
Fig. 4 Ratio of left to right lung weight before and after treatment with vitamin A (E9.5) (P b .05: *nitrofen vs CDH; wnitr+vitA
vs CDH+vitA).
M.J. Baptista et al.662At E20, there began to be more lung hypoplasia in
the CDH than in the nitrofen group. The ratio of lung to
body weight was 21% and 25% lower than in the baseline
group in the nitrofen and CDH groups, respectively. At this
time point, prenatal treatment with vitamin A had aTable 1 Developmental changes in LL protein, DNA, and
protein/DNA ratio of baseline rats, nitrofen-exposed rats, and
vitamin A–treated rats
Gestational day
E18 E20 E22
LL protein/BW (mg/g)
Baseline 0.84 F 0.03 0.89 F 0.04 0.68 F 0.02
Nitrofen 0.49 F 0.04a 0.71 F 0.04a 0.54 F 0.02a
CDH 0.48 F 0.02a 0.60 F 0.04a 0.43 F 0.02a
Nitr+vitA 0.62 F 0.02 0.91 F 0.04b 0.65 F 0.05b
CDH+vitA 0.52 F 0.02 0.80 F 0.03c 0.53 F 0.04c
LL DNA/BW (lg/g)
Baseline 90 F 4 104 F 6 59 F 3
Nitrofen 55 F 7a 79 F 5a 46 F 2a
CDH 52 F 2a 76 F 3a 38 F 3a
Nitr+vitA 64 F 3 105 F 3b 56 F 5b
CDH+vitA 53 F 3 86 F 1c 44 F 1c
Protein/DNA ratio
Baseline 9.6 F 0.5 8.5 F 0.3 11.8 F 0.6
Nitrofen 9.7 F 0.1 9.5 F 0.6 12.0 F 0.5
CDH 9.4 F 0.5 8.9 F 0.7 12.2 F 0.1
Nitr+vitA 9.7 F 0.4 8.9 F 0.4 11.8 F 0.9
CDH+vitA 9.8 F 0.9 9.3 F 0.8 12.2 F 0.9
BW indicates body weight.
a P b .05: versus baseline.
b P b .05: versus nitrofen.
c P b .05: versus CDH.tremendous effect on the ratios of lung to body weight
in fetuses from both nitrofen-exposed groups. In fact,
treatment with vitamin A improved ratio of lung to body
weight by a similar proportion (14%) in both nitrofen-
exposed groups (Fig. 2).
By the end of gestation (E22), lung hypoplasia was
significantly worse in the CDH group (38% lower than the
baseline group) than in the nitrofen group (10% lower than
the baseline group). Interestingly, vitamin A treatment
resulted in improvement of the ratio of lung to body weight,
which represented an attenuation of lung hypoplasia of 9% in
both groups (Fig. 2).
Regarding the behavior of left and right lung develop-
ment, we evaluated left or right lung hypoplasia by
correspondent ratios of lung to body weight (Fig. 3) as well
as ratio of left to right lung weight (Fig. 4). We observed that
both lungs suffered from a similar degree of hypoplasia at
E18 in both the nitrofen and CDH groups (Fig. 3).
Consequently, no significant differences were observed in
ratio of left to right lung weight among all studied groups at
E18 (Fig. 4). At E20, the degree of LL hypoplasia, in the
CDH group, increased to 32%, whereas the right lung
hypoplasia remained similar to that observed at E18
(approximately 20%) (Fig. 3). Therefore, in contrast to
E18 where the ratio of left to right lung weight was similar, at
E20, there was a significant decrease of ratio of left to right
lung weight primarily because of LL underdevelopment
(Fig. 4). At E22, lung hypoplasia in the CDH group
increased for both lungs, although it remained more
pronounced in the left side (Fig. 3). Thus, ratio of left to
right lung weight was significantly reduced in the CDH
group. Interestingly, antenatal administration of vitamin A
Fig. 5 Ratio of lung to body weight in before and after late-gestational (E18) treatment with vitamin A. Late antenatal administration of
vitamin A did not affect lung growth (P b .05: *nitrofen vs CDH; wnitr+vitA vs CDH+vitA).
Vitamin A and lung development in CDH 663did not change these ratios at any gestational time point
(Fig. 4). These results demonstrated that the effect of vita-
min A on lung growth is of similar magnitude in both lungs.
Biochemical analysis of lung protein and DNA content
(normalized to body weight) confirms the results obtained
from morphological studies. Meanwhile, there was no sig-
nificant difference in the DNA/protein ratio between groups
that were treated or not treated with vitamin A (Table 1).
2.2. Late (E18.5) administration of vitamin A
Late administration of vitamin A did not affect the
incidence of CDH in fetuses exposed to nitrofen. Moreover,
analysis of ratio of total lung to body weight at E22
revealed no effect of late vitamin A administration (Fig. 5).3. Discussion
In the rat nitrofen-induced CDH model, it has been
previously demonstrated that lung hypoplasia has distinct
early and late gestational determinants [30,31]. Early
determinants appear to be directly related to the chemical
effects of nitrofen, whereas late determinants seem to be
primarily related to mechanical factors mediated by visceral
thoracic herniation. This 2-hit hypothesis for lung hypopla-
sia, although not yet demonstrated to be relevant to human
CDH, would have profound implications for antenatal
pharmacological therapy. Because human CDH is rarely
diagnosed before 16 weeks’ gestation [32,33], early
determinants of lung hypoplasia would essentially be
completed by the time the diagnosis is made. Thus, itwould be too late for pharmacological manipulations that
counteract the nonmechanical phase of the pathophysiology.
Several previous studies have suggested that retinoids
might have an important role in the pathogenesis of CDH
[18,19,21,24-26]. As early as 1953, Wilson et al [27]
demonstrated that the offspring of pregnant rats maintained
on a vitamin A–deficient diet have a high incidence of
CDH. Studies of retinoid receptors double null–mutants
mice, lacking both a and b subunits of RAR, have
demonstrated that a significant proportion of the offspring
has lung agenesis/hypoplasia and/or diaphragmatic defect
[21]. Furthermore, infants with CDH have 50% less plasma
retinol and retinol-binding protein than age-matched con-
trols [34]. More recently, it was proven that nitrofen-induced
CDH is secondary to the inhibition of retinal dehydrogenase
(RALD2), a key enzyme necessary for the production of
retinoic acid, which is expressed in the developing lung and
diaphragm [25]. All these evidences suggest that, in the
CDH, there are an important role of retinoids signaling and
that, in the CDH rat nitrofen-induced model, the disturbed
molecular pathway is the same that is abnormal in human
fetuses with CDH. Evidence for this is tightly supported
from several references to an association of CDH with
chromosome 15q defects, which encodes for cellular
retinoic acid–binding protein-1 [26]. The´baud et al [14,15]
demonstrated, in the nitrofen rat model, that a single dose of
prenatal vitamin A increases survival, decreases the
incidence of CDH, and increases lung growth. All these
previous studies were designed to evaluate the effect of
early administration of vitamin A at term gestation [14,15].
Such an approach did not have adequate discrimination to
M.J. Baptista et al.664allow investigation of the effect of antenatal vitamin A on
early and late determinants of lung hypoplasia.
We have previously demonstrated in the rat nitrofen-
induced CDH model that late determinants of lung hypo-
plasia begin to influence lung growth after E18 [28]. These
determinants are probably related to the mechanical effect on
the lung, secondary to the presence of herniated viscera in
the thorax. This hypothesis is supported by lung mechano-
transduction studies [35-38]. In fact, growth and maturation
of fetal lung are regulated by humoral and physical factors.
Mechanical stretch, mediated by fluid-derived airways
expansion and fetal breathing movements, effectively
regulates the responsiveness of cells to growth factors by
up-regulating the expression of related receptors, which can
further mediate cell proliferation through autocrine and/or
paracrine mechanisms [35-38]. We believe that late deter-
minants of lung hypoplasia are related to interference with
this mechanical (physical) forces acting on lung in late
gestation. In contrast, determinants related to the molecular
effect of nitrofen in the retinoid signaling pathway act early
in gestation, interfering not only with lung development but
also with heart and diaphragm development.
In the current study, we could assess the effect of
administration of vitamin A on lung growth, during the
3 stages of lung development: pseudoglandular (E18),
canalicular (E20), and alveolar (E22) [39]. We confirmed
that lung hypoplasia was similar in both nitrofen-exposed at
E18. Only at E20 could a difference in lung hypoplasia
between nitrofen and CDH groups be demonstrated, and this
difference only became clearly significant at E22 (Figs. 1 and
2). The appearance of this divergence in lung growth between
the nitrofen and CDH groups marks the beginning of the
mechanical determinants of lung growth in this model [28].
Interestingly, when we examined right and left lung
development independently during gestation, it was clear
that left and right lung development is differentially
influenced by late determinants. The hypoplasia induced
by mechanical effects becomes apparent at different
gestational ages. Because we interpret a reduction in lung
size in the CDH group compared with the nitrofen group to
mark the beginning of the mechanical phase of reduction in
lung growth in this model, the observation of a differential
in LL hypoplasia at E18 versus a differential in right lung
hypoplasia at E22 (Fig. 3) clearly suggests that mechanical
effects influence LL development much sooner than right
lung development. In this context, we propose that ratio of
left to right lung weight can be used as a direct index to
monitor the influence of mechanical factors. In fact, as
analyses of Fig. 4 suggests, this index is only significantly
influenced by the presence of CDH. Over the interval E18 to
E22, we observed that the effect of CDH on this index
increases progressively, which should be attributable to the
increasing influence of mechanical factors on lung devel-
opment in CDH fetuses as gestation proceeds.
Antenatal administration of vitamin A (E9.5) produced
beneficial effects at all studied gestational time points. Infact, our study confirms the findings of The´baud et al which
demonstrate a clear attenuation of lung hypoplasia,
expressed as ratio of lung to body weight and lung DNA
and protein content after early treatment with vitamin A.
This improvement is mediated by cell proliferation, because
the protein/DNA ratio remains unchanged.
Thus, lung growth enhancement because of vitamin A
varies during gestation, becoming more pronounced at E20
when lung growth velocity reaches its peak. At each time
point, however, antenatal vitamin A administration attenu-
ates lung hypoplasia to a remarkably similar degree in
nitrofen and CDH groups (Fig. 2). In fact, vitamin A
administration did not change the percentage difference in
lung hypoplasia observed between the nitrofen and CDH
groups documented at E20 and E22. These results clearly
indicate that vitamin A attenuates lung hypoplasia by
interfering with early acting factors.
In CDH groups, vitamin A did not interfere with the ratio
of left to right lung weight at any studied time point. As the
ratio of left to right lung weight can be considered a direct
index of the action of late determinants of lung hypoplasia,
this result reinforces our hypothesis that vitamin A cannot
restore late mechanically induced lung hypoplasia secondary
to thoracic visceral herniation. This conclusion is further
supported by the observation that late administration of
vitamin A did not affect lung development. We therefore
speculate that the benefit from antenatal administration of
vitamin A is only because of its direct action on the molecular
substrate where the effects of nitrofen are manifest. This
could be related to the hypothesis that vitamin A effectively
promotes lung budding and bronchial morphogenesis early in
gestation, providing the embryonic lung additional potential
for growth in subsequent stages of development [18,24].
Our results raise doubts as to whether vitamin A could be
beneficial in the treatment of human fetuses with CDH. In
clinical practice, the prenatal diagnosis of CDH occurs
relatively late in gestation, usually after 16 weeks’ gestation
(corresponding to E18 of lung development in rat).
Although in previous studies vitamin A appeared to be
promising for the treatment of lung hypoplasia in CDH, our
results with late (E18.5) gestational administration, an
equivalent time point to when human fetuses would first
be diagnosed with CDH showed no benefit.
In conclusion, in contrast to late determinants of lung
hypoplasia, vitamin A appears to act only on the early
pathways that ultimately lead to the diaphragmatic defect
and pulmonary hypoplasia. This has relevant clinical
implications because in human beings, prenatal diagnosis
of CDH commonly occurs after 16 weeks’ gestation.Acknowledgments
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HEART MATURITY IN CONGENITAL DIAPHRAGMATIC HERNIA  
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Background: Previous morphological studies had produced controversial results with regard to heart
development in congenital diaphragmatic hernia (CDH), whereas a few publications investigated cardiac
function and myocardial maturation. Myocardium maturation is associated with age-dependent
increasing of gene expression of gap junction protein connexin 43 (Cx43), adenosine triphosphatase
of the sarcoplasmic reticulum (SERCA2a), as well as switching of myosin heavy chains (MHCs) from
b to a isoforms. Our aim was to evaluate myocardium maturity in nitrofen-induced CDH rat model.
Methods: Fetuses from dated pregnant Sprague-Dawley rats were assigned to 3 experimental groups:
control, nitrofen (exposed to nitrofen, without CDH), and CDH (exposed to nitrofen, with CDH).
Myocardial samples collected from left ventricle free wall were processed to (i) quantification of
messenger RNA (mRNA) of Cx43, SERCA2a, a and b MHC isoforms, as well as b-actin (housekeeping
gene); and (ii) separation of MHC isoforms (a and b isoforms) by sodium dodecyl sulfate polyacrylamide
gel electrophoresis silver stained.
Results: We demonstrated that there is no difference in myocardial gene expression of Cx43 (control,
1.0 F 0.1; nitrofen, 1.1 F 0.2; CDH, 1.3 F 0.2) and SERCA2a (control, 1.0 F 0.1; nitrofen, 0.9 F 0.1;
CDH, 1.0 F 0.2). Myocardial gene expressions of a and b mRNA of MHC isoforms were slightly
decreased both in nitrofen and CDH fetuses when compared with control fetuses, but evaluation of the a-Journal of Pediatric Surgery (2006) 41, 1532–1538Elsevier Inc. All rights reserved.
at the 51st Annual International Congress of the British Association of Paediatric Surgeons, Oxford, England,
ieˆncias da Sau´de, Universidade do Minho, 4709-057 Braga, Portugal. Tel.: +351 253 604 807; fax: +351 253 604 831.
o.pt (J. Correia-Pinto).
Myocardium expression of connexin 43 1533to-b ratios of MHC isoforms at protein level revealed no significant differences between CDH and control
(control, 16.9 F 2.5; CDH, 17.0 F 2.0).
Conclusions:Myocardial quantification of Cx43 and SERCA2a mRNA, as well as the expression pattern
of MHC isoforms at protein levels, was similar in all studied groups.We predict, therefore, that acute heart
failure commonly observed in CDH infants might be attributed predominantly to cardiac overload
secondary to severe pulmonary hypertension rather than to myocardial immaturity.
D 2006 Elsevier Inc. All rights reserved.Despite improvements in perinatal care, the mortality of
fetuses and newborns with congenital diaphragmatic hernia
(CDH) remains exceedingly high [1]. This mortality is
related to severe pulmonary hypoplasia and pulmonary
hypertension [2]. Nevertheless, some authors had suggested
that, even in the absence of congenital heart disease, these
patients could suffer some cardiac underdevelopment that
might further worsen their prognosis [3-5].
Research in experimental CDH had documented that there
are 2 determinants of lung hypoplasia [6]: early in gestation,
lung underdevelopment seems to be linked to molecular
factors, whereas late determinants are related to mechanical
compression from herniated organs. On the other hand, heart
development in CDH appears to be influenced only by early
factors acting during fetal growth [7,8]. In fact, in the nitrofen
rat model of CDH, we demonstrated that heart hypoplasia
occurs early in gestation, but disappears as gestation proceeds
to term, suggesting that late determinants do not influence
heart development in CDH [8]. Nevertheless, although
morphologically normal at the end of gestation, the heart
could be functionally immature. It remains to be clarified,
therefore, if myocardium in CDH fetuses is more immature
than age-matched controls, as described for lung [2,9].
Systolic and diastolic cardiac function in normal fetuses
and newborns has less reserve than in the adults. Studies in
experimental models demonstrated that systolic pump
performance and contractility are developmentally regulated
processes that improve throughout gestation and during
postnatal life [10]. Active and passive cardiac relaxation and
global diastolic function also improve as a function of
perinatal age [11-13]. These changes in cardiac function
typically are accomplished by qualitative and/or quantitative
alterations in cardiomyocyte-specific gene expression. Such
adaptation occurs at different levels either at cell-to-cell
communication as well as at intracellular calcium kinetics
and contractile proteins.
At the cell-to-cell communication level, connexin 43
(Cx43) is a major constitutive protein of the gap junctions in
the mammalian myocardium involved in the electrical
coupling of myocytes [14]. Abundance of Cx43 is develop-
mentally regulated. In fact, it was already demonstrated that
the extent of Cx43 expression in the ventricles progressively
increases during development [15].
At the intracellular level, sarcoplasmic reticulum Ca2+-
adenosine triphosphatase (SERCA2a) controls calcium
reuptake by the sarcoplasmic reticulum from the cytosol
during diastole. During early fetal development, calciumexchanges in ventricular myocardium are mainly controlled
by the Na+-Ca2+ exchanger of the plasma membrane,
whereas SERCA2a plays an important role only at the end
of gestation and after birth [16]. Myocardial maturation is
accomplished by an increase in transcription of SERCA2a
messenger RNA (mRNA) as gestation proceeds to term.
Myosin is a hexameric contractile protein, composed of
2 myosin heavy chains (MHCs), which hydrolyses adeno-
sine triphosphate required for cardiac muscle contraction.
Mammalian cardiac muscle can express 2 MHC isoforms:
a and b. The a isoform (a-MHC) is associated with a
higher adenosine triphosphatase activity than the b isoform
(b-MHC). The specific pattern of cardiac MHC isoform
expression changes during development and strongly
influences the contractile properties and energetics of the
heart during fetal growth [17-22].
In heart failure and pressure overload fetal models, it was
previously demonstrated a dowregulation of Cx43 [23] and
SERCA2a [24], reflecting myocardial stress and immaturity.
In addition, evaluation of myocardial a-to-b ratio of MHC
isoforms has been suggested as a molecular marker of
myocardial maturation and adaptation to atrophy, hypertro-
phy, failure, and hypoplasia.
The aim of the current study was to evaluate, in the
nitrofen-induced CDH rat model, gene expression of
different cardiac molecular parameters that are developmen-
tally regulated in an attempt to detect any molecular signs of
myocardium immaturity.1. Materials and methods
The protocols used in this investigation were approved
by the Institutional Animal Care and Use Committee and
conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH publication no. 85-23, revised 1996).
1.1. Animal model
Seven female Sprague-Dawley rats (225 g; Criffa, SA,
Barcelona, Spain) were pregnant after controlled overnight
mating, and the finding of vaginal plug was counted as day 0.
Pregnant rats were exposed on 9.5 days post coitum to
100 mg of nitrofen (2,4-dichlorophenyl-p-nitrophenylether)
dissolved in 1 mL of olive oil administered by gavage or with
an equal volume of olive oil alone [25]. Fetuses were har-
vested by cesarean section at day 21.5 (term gestation,
M.J. Baptista et al.153422 days) and weighed on a precision balance (Scaltec
Instruments SBC 21, Heiligenstadt, Germany). After fetal
decapitation, under binocular surgical microscopy (Leica,
Wild M651.MS-D, Heerbrugg, Switzerland), laparotomy
was performed to inspect the diaphragm. Lungs and hearts
were excised in bloc through median sternotomy. Heart and
left lung were weighed, and their wet weights were
expressed as a percentage of fetal body weight. Myocardial
samples were harvested from left ventricular free wall,
weighed, and snap frozen at 808C for further molecular
studies. Fetuses were assigned to 3 experimental groups: (i)
control group, fetuses exposed to olive oil alone, without
CDH; (ii) nitrofen group, fetuses exposed to nitrofen without
CDH; (iii) CDH group, fetuses exposed to nitrofen with
CDH. Fetuses with structural cardiac defects were excluded.
1.2. Molecular studies
1.2.1. Ribonucleic acid extraction
Total mRNA from left ventricle sample of 30 fetuses
(Control group n = 10, Nitrofen group n = 10, CDH group
n = 10) was extracted using the RNeasy Mini Kit Protect
(74712; Qiagen, Germany). Quantification of total mRNA
was done by spectrophotometry (BioPhotometer; Eppendorf,
Germany), and the ratio A260/A280 was used to test protein
and deoxyribonucleic contamination of the extracted product.
1.2.2. Reverse transcription
Each sample of mRNA was diluted until it reaches
50 ng/lL; for the complementary DNA (cDNA) transcrip-
tion reaction, 2 lL was used (100 ng). The reverse
transcription was carried out on a T-gradient thermoclycer
(Biometra, Germany) using the kit Superscript II (48190-
001; Invitrogen). Briefly, 1 lL of 125 ng/lL random
primers (48190-001; Invitrogen), 4 lL of 5 buffer, 2 lL of
1 mmol/L 1,4-dithiothreitol (DTT), 1 lL of 10 mmol/L
deoxyribonucleotide triphosphate (dNTP) mix (R0192; MBI
Fermentas), 1 lL of recombinant Rnasin (N2515; Prom-
ega), and 1 lL of Superscript II reverse transcriptase were
added in a total volume of 20 lL. The following program
was used to carry on the reverse transcriptase reaction: 428C
for 60 minutes and 708C for 15 minutes. In all the reactions,
a negative control, omission of mRNA, was used.Table 1 Primers used for quantitative PCR
Gene Accession no. Primer set
a-MHC NM_017239 5V-GCTTTGGGAAGT
5V-GCCTTTAGCTGGA
b-MHC NM_017240 5V-CTGAGGAGGCGG
5V-CTTGGCGCCAATG
Cx43 NM_012567 5V-GATTGAAGAGCA
5V-GTGTAGACCGCG
SERCA2a NM_017290 5V-TGGTCTGTATCTT
5V-CCAGATCTGGAG
b-actin NM_031144 5V-GAT TTG GCA CC
5V-ACT TTG GTC AT1.2.3. Quantitative polymerase chain reaction
Accordingly to a 2-step model, the obtained total cDNA
was used for the relative quantification by real-time poly-
merase chain reaction (PCR) of SERCA2a, Cx43, a-MHC,
b-MHC, and of the reference geneb-actin. The PCR reactions
were prepared for the LightCycler (Roche, Germany). Each
run for all gene quantification consisted of 15 minutes of
hot-start and 55 cycles (958C for 15 seconds, 588C for
20 seconds, 728C for 15 seconds). The following protocol
was used for each capillary (11909339001, Roche): 10 lL of
SYBR Green (204143, QuantiTech SYBRgreen PCR;
Quiagen, Germany), 2 lL of cDNA, and 10 pmol of each
primer (Thermo Electron, Germany) were added in a total
volume of 20 lL. A negative control was included in all the
runs, which consisted in omitting the cDNA and performing
a melting curve analysis, thus, allowing the detection of
putative contamination.
Primer design was based on the available sequences in
GenBank (NCBI-NLM-PubMed-Gene). All the primers are
intron spanning (Table 1). For all the primer sets, standard
amplification curves were made with randomly selected
cDNA samples setting, r = 0.99. In every quantitative run,
3 replicas of the standard ST-100 ng were included as
internal controls and quantitative references for the vari-
ability of the procedure. In all the samples, gene expression
was normalized for b-actin.
1.2.4. Myosin heavy chain protein isoforms
We evaluated the content of protein MHC isoforms in
control and CDH fetuses. For that, left ventricular samples
from 15 fetuses (control group, n = 7; CDH group, n = 8)
were homogenized in a solution: 50 mmol/L N-[2-hydrox-
yethyl]piperazine-N’-[2-ethanesulfonic acid] (HEPES) (USB
16928), 150 mmol/L KCl (Merck 1.04936), 1 mmol/L
phenylmethylsufonyl fluoride (PMSF) (Sigma P-7626),
1 mmol/L DTT (PlusOne 17-1318-02), 0.1 mmol/L CLAP
(chemostatin, leupeptin, antipain, pepstatin). The entire
protein content of each sample was obtained by spectropho-
tometry using the Bradford method (BioRad 500-0002).
Twenty micrograms of the total protein content from each
sample were separated by electrophoresis in 10% stacking
and 5% separating sodium dodecyl sulfate polyacrylamideProduct size (base pair)
TCATCAG-3V 109
AGATCAC-3V
AGGAACAG-3V 146
TCACG-3V
CGGCAAGG-3V 144
CTCAAG-3V
CCTGACG-3V 129
GATTGAAC-3V
A CAC TTT CTA CA-3V 114
C TTT TCA CGG TTG G-3V
Fig. 1 Left lung-to-body weight (LLW-BW) and heart-to-body
weight (HW-BW) ratios in control, nitrofen, and CDH groups at
term of gestation (P b .05 vs *control group, vs wnitrofen group).
ig. 3 Expression of SERCA2a mRNA in control, nitrofen, and
DH groups expressed in arbitrary units normalized for b-actin.
Myocardium expression of connexin 43 1535gels (60 V, 240 minutes). Subsequently, a and b MHC
isoforms were identified by comparison with a molecular
weight standard (161-0373 BioRad) after silver staining
(BioRad 161-0449) with a continued agitation to obtain a
uniform staining across gels. Relative quantification of MHC
isoforms was achieved through scanning densitometry (white
light; Alpha innotech Alpha Imager 2200).
1.3. Statistical analysis
Results were presented as mean F SEM. The different
data sets of control, nitrofen, and CDH groups failed in the
Kolmogorov-Smirnov test for normality. Therefore, statis-
tical analysis was performed by the 1-way analysis of
variance on ranks, and the Dunn test for posttest analysis.
Statistical significance was set at P b .05.2. Results
From fetuses exposed to nitrofen, 58% had diaphrag-
matic defect. At term, the left lung-to-body weight ratio was
significantly reduced in CDH group in comparison to non-Fig. 2 Expression of Cx43 mRNA in control, nitrofen, and CDH
groups expressed in arbitrary units normalized for b-actin.F
CCDH groups. In contrast, the heart-to-body weight ratios
were not significantly different (Fig. 1).
The levels of mRNA (normalized to b-actin) of both
Cx43 (Fig. 2) and SERCA2a (Fig. 3) were similar between all
studied groups. Regarding MHC isoforms, we demonstratedFig. 4 Expression of a (A) and b (B) MHC isoforms mRNA in
control, nitrofen, and CDH groups expressed in arbitrary units
normalized for b-actin.
Fig. 5 A, Representative gel with separation of a and b MHC
isoforms in control and CDH groups. B, a-to-b ratios of MHC at
protein level.
M.J. Baptista et al.1536that myocardial gene expressions of a and b mRNA of
MHC isoforms were slightly decreased both in nitrofen and
CDH fetuses when compared with control fetuses (Fig. 4).
To confirm these results, we performed additional studies
to evaluate a-to-b ratios of MHC isoforms at protein level.
Despite similar molecular masses of rat protein a-MHC and
b-MHC (~223 kd, with difference b0.2%), we achieved
consistent separation of both protein isoforms from small
samples of myocardium with selected electrophoresis
protocol. In separating gels applied, b-MHC migrated
farther than a-MHC, as expected (Fig. 5A). Our results
demonstrated that control fetal rat’s left ventricle expresses
predominantly a-MHC protein isoform with only a small
amount of b-MHC, and this pattern is similar in fetuses with
CDH (a-MHC control, 94% F 0.6; CDH, 95% F 0.6).
Regarding MHC a-to-b ratio, we verified that this parameter
of molecular adaptation did not change in fetuses with
diaphragmatic defect, because there is no statistical differ-
ence in comparison to control group (Fig. 5B).3. Discussion
Congenital diaphragmatic hernia is a rare (1:2500) con-
genital malformation with a mortality that remains ex-
ceedingly high regardless of sophisticated managementtechniques, such as extracorporeal membrane oxygenation
and fetal tracheal occlusion [1,26]. The leading causes of
mortality in CDH are pulmonary hypoplasia and severe
persistent pulmonary hypertension, but the presence of
chromosomal anomalies and/or congenital heart disease
worsens the prognosis of these patients [5].
The link between the heart and lung development in
CDH was emphasized by several authors [3-5,8]. In fact,
CDH is a complex disease, probably related to an early
imbalance in retinoid signaling that occurs in a critical
temporal window, interfering not only with diaphragmatic
closure, but also with the development of several organs
such as lung and heart [27,28]. In this sequence, it has been
suggested that even the fetuses that do not present heart
malformations could have some type of cardiac molecular
changes. In previous studies, some investigators have
reported significant heart hypoplasia [29] and structural
immaturity of the heart in rat fetuses with CDH [9]. In the
CDH rat model, the dual-hit hypothesis defines that there
are 2 determinants of lung hypoplasia: early determinants
are related to molecular factors likely secondary to
disturbances in retinoid signaling, whereas late determinants
are related to mechanical compression secondary to organ
herniation [6-8]. We previously demonstrated that during
fetal development, the heart is only affected by early
determinants. In fact, early in gestation, there is evidence
of heart and lung hypoplasia, but as gestation proceeds to
term, lung hypoplasia increases, whereas heart hypoplasia
recovers to normal [8]. Interestingly, this recovery seems to
occur also in humans. In fact, during fetal life, the
echocardiographic evaluation of left ventricular size was
suggested to be useful in predicting the outcome of fetuses
with CDH [4,5,30], whereas at end gestation, recent studies
failed to document significant heart hypoplasia and useful-
ness in estimation of left ventricular mass to predict the
outcome in infants with CDH [31,32]. Even in these
conditions, it has been suggested by some authors that the
left ventricle at delivery in CDH infants could be less
compliant and less able to maintain the systemic circulation.
In this sequence, we hypothesized that left-ventricular
myocardium could be functionally immature, although
morphologically normal at the end of gestation.
Evaluation of cardiac function in rat newborns is hard-
ly performed because of reduced dimensions of pups. To
overcome this limitation, we selected some genes that
are developmentally regulated and sensible to load condi-
tions. For these reasons, we evaluated myocardial maturity
through gene expression of Cx43, SERCA2a as well as
MHC isoforms.
It is important to highlight that in our study, we did not
include fetuses with cardiac congenital malformations
because congenital heart disease can modify the global
heart weight as well as molecular parameters of maturity. In
addition, as molecular parameters of maturity could be
affected by toxic effect of nitrofen, we included in our study
fetuses exposed to nitrofen without CDH.
Myocardium expression of connexin 43 1537Connexin 43 is important for myocardial communication
through gap junction, which is essential for myocardial
electrical activity, heart differentiation, and function since
the early stages of heart morphogenesis [14,15]. SERCA2a
is a sarcoplasmic pump involved in calcium reuptake that
regulates either inotropic or lusitropic reserve of the fetal
heart [11,16]. Interestingly, we could not detect significant
changes on myocardial expression of Cx43 and SERCA2a
neither in nitrofen nor in CDH groups. Based on these
results, we predict no significant functional myocardial
disturbances owing to electrical or calcium kinetics issues in
the nitrofen-exposed fetuses.
Regarding contractile proteins, myocardial a-to-b ratio of
MHC isoforms has been used as an appropriate index to
predict both cardiac maturation and dysfunction [18-21]. In
fact, the ratio of MHC isoforms changes during fetal
development as heart maturation occurs [20], whereas in
cardiac dysfunction (both in experimental models and in
human disease), it was demonstrated as overexpression of
b-MHC isoform [33,34]. Myosin heavy chain isoforms
expression has been suggested, therefore, as a molecular
marker either of myocardium maturation or of adaptation to
atrophy, hypertrophy, failure, and hypoplasia [18-21]. In our
study, myocardial gene expressions of a and b mRNA of
MHC isoforms were slightly decreased both in nitrofen and
CDH fetuses, but evaluation of the a-to-b ratios of MHC
isoforms at protein level revealed no significant differences
between CDH and control. This suggests that CDH hearts
were not associated with myosin isoform immaturity in com-
parison with age-matched controls. Interestingly, Okazaki
et al [35] also studied the expression of myosin isoforms in
pulmonary vasculature of CDH rats, and their results in the
lung were similar to ours in the heart. Pulmonary vasculature
myosin isoform SMem is predominantly expressed in
immature smooth muscle cells, whereas SM2 isoform is
expressed in mature smooth muscle cells. The authors found
that, in the rat model of CDH, there is no difference in pul-
monary smooth muscle cell differentiation in CDH fetuses: in
both control and CDH groups, SMemb expression was
positive from 16 days’ gestation, whereas SM2 expression
was negative in vessel walls during the prenatal life.
In our point of view, these results provide also additional
molecular evidence to reinforce morphological data, which
established that no significant left ventricular hypoplasia
occurs in CDH fetuses at end gestation [7,8]. In fact, it was
suggested that the major pathophysiologic mechanism of the
relative underdevelopment of the left side of the heart in
CDH is probably an unloading of the left ventricle owing to
a combination of decreased pulmonary venous return
because of diminished lung mass and a decreased interatrial
shunt [30]. In adult rats, Depre et al [36] demonstrated that
chronic unloading could reactivate the molecular fetal
phenotype of myocardium (increase of b MHC isoform).
It seems reasonable, therefore, to hypothesize that if
left ventricular hypoplasia would occur secondary to the
abovementioned mechanism (unloading), left ventricularmyocardium would present delayed maturation, which we
could not demonstrate.
In conclusion, we demonstrated in the nitrofen-induced
CDH rat model that at term of gestation, there is no
evidence of myocardial immaturity. In this sequence, we
predict that acute neonatal heart failure commonly observed
in CDH infants might be attributed predominantly to cardiac
overload secondary to severe pulmonary hypertension rather
than to myocardial intrinsic disturbances.References
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Abstract
Background: In congenital diaphragmatic hernia (CDH), pulmonary hypertension increases right
ventricle (RV) afterload, which could impair heart function and contribute to poor outcome for most
affected infants. Nevertheless, the real significance of vascular pulmonary alterations in perinatal
hemodynamics is largely unknown. It is defined that ventricular pressure overload induces increased
myocardium gene expression of B-type natriuretic peptide (BNP) and components of the renin-
angiotensinogen and endothelin (ET)–1 systems. Our aim was to evaluate perinatal myocardium
expression of these genes associated with ventricular pressure overload in a nitrofen-induced CDH
rat model.
Methods: In the nitrofen-induced CDH rat model, fetuses from dated pregnant Sprague-Dawley rats at
15.5, 17.5, 19.5 and 21.5 days postcoitum as well as newborn pups were assigned to 3 experimental
groups: control, nitrofen (exposed to nitrofen, without CDH), and CDH (exposed to nitrofen, with
CDH). Myocardial samples collected from the RV and left ventricle (LV) were processed for
quantification of messenger RNA (mRNA) of BNP, angiotensinogen, and ET-1.
Results: The perinatal expression of BNP, angiotensinogen, and ET-1 mRNA in the RV and left
ventricle of the control group revealed daily changes. During gestation, the expression of BNP and
angiotensinogen mRNA underwent significant oscillation compared with control in both nitrofen-
exposed fetuses, although we cannot identify significant differences between the nitrofen and CDH
groups. After birth, we found a significant increasing expression of all studied genes only in the RV of
CDH pups.
Conclusions: Perinatal myocardial quantification of BNP, angiotensinogen, and ET-1 mRNA levels
suggests that both nitrofen-exposed and control pups revealed prenatal variations of expression of the
studied genes. Moreover, CDH is associated with significant molecular alterations only in the RV
after birth.
© 2007 Published by Elsevier Inc.U
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oi:10.1016/j.jpedsurg.2007.08.0444Despite improvements in perinatal care, the mortality of
4fetuses and newborns with congenital diaphragmatic hernia
4(CDH) remains exceedingly high [1]. This mortality seems to
4be related with severe pulmonary hypoplasia and pulmonary
4hypertension (PH) [2]. Several authors suggested that, even
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in the absence of congenital heart disease, these infants could
experience of some degree of cardiac underdevelopment
[3,4]. In previous studies, we demonstrated in the experi-
mental rat model of CDH the absence of left ventricle (LV)
hypoplasia [5,6] or myocardium immaturity [7] in CDH
fetuses. Nevertheless, the real significance of increased right
ventricle (RV) afterload, because of neonatal PH, in heart
function is still unknown.
Another question that still persists in CDH is the true
significance of PH in fetal hemodynamics and its con-
sequences for the fetal heart. In infants with CDH,
pulmonary vascular modifications occur from early stages
of prenatal development [8] and assume obvious significance
after birth. Nevertheless, their meaning in fetal heart function
is uncertain. Because fetal heart function is not easily
assessed by ultrasonography, the evaluation of markers of
ventricular overload in an experimental model of CDHmight
provide an appropriate alternative. Several biochemical and
genetic markers have been suggested to evaluate ventricular
load and function, both in animal models and humans, such
as B-type natriuretic peptide (BNP), components of the
renin-angiotensin system, and endothelin (ET)–1[9].
B-type natriuretic peptide is a hormone of predominantly
ventricular origin produced and released in response to
increased ventricular wall stress [10,11]. In recent years, it
has emerged as a very sensitive biochemical marker for
ventricular dysfunction in heart failure as well as in PH, and
its plasmatic level could be used to guide the response to
therapy and to predict prognosis [12,13]. During normal fetal
rat development, a very intense expression of BNP in the
heart from 9.5 days postcoitum (dpc) was demonstrated, with
major peaks of expression in stages that coincide with
landmarks in heart development [14].
The components of the renin-angiotensin system and their
roles in adult cardiac hypertrophy have been well documen-
ted [15,16]. In adult hearts, the increased hemodynamic load
results in increased levels of angiotensin II that stimulates
significant hypertrophy and remodeling of cardiac structure.
Recent evidence from in vivo studies indicates that
angiotensin II also acts as a growth factor and has a potential
role in embryonic, fetal, and neonatal development of the
heart [17-19]. In addition, the AT1 and AT2 angiotensin II
receptor subtypes are present in the heart and are
developmentally regulated [20].
Endothelin 1 is a potent vasoconstrictor peptide derived
from endothelial cells that is also produced by cardiac
myocytes [21]. Endothelin 1 induces myocardial cell
hypertrophy and has potent positive inotropic and chrono-
tropic effects on isolated heart muscle. These actions are
mediated by the receptors for ET-1 (ETA and ETB receptors)
on the cardiac myocytes [22]. The production of ET-1 in the
heart is increased in pressure overload conditions, such as PH
[23]. Several studies demonstrated that ET system has an
important role in the developing heart, contributing to the
formation of anatomical structures such as heart outflow tract
and great vessels [24].F
Interestingly, it was suggested in several previous studies
that natriuretic peptides, angiotensin II, and ET-1 could play
a significant role in the PH associated with CDH [25-29].
Moreover, in the rat model of CDH, several authors reported
significant modifications in heart expression of components
from all these systems. Nevertheless, none of these studies
assessed the messenger RNA (mRNA) expression of all
these genes in both ventricles throughout gestation [30-32].
The aim of the current study was to evaluate, in the
nitrofen-induced CDH rat model, LV and RV mRNA
expression of BNP, angiotensinogen, and ET-1, genes
previously defined as ventricular overload markers, in an
attempt to evaluate the significance of PH in myocardium
molecular adaptation during fetal development and transition
after birth.TE
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RO1. Materials and methods
The protocols used in this investigation were approved by
the Institutional Animal Care and Use Committee and
conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(publication no. 85-23, revised 1996).
1.1. Animal model
Pregnancy was obtained in 22 female Sprague-Dawley
rats (225 g; Criffa, SA, Barcelona, Spain) after controlled
overnight mating, and the finding of vaginal plug was
counted as day 0. At 9.5 dpc, pregnant rats were exposed to
100 mg of nitrofen (2,4-dichlorophenyl-p-nitrophenylether)
dissolved in 1 mL of olive oil administered by gavage or to
an equal volume of olive oil alone [33]. Randomly, fetuses,
treated with nitrofen or olive oil, were harvested by cesarean
section at 15.5, 17.5, 19.5, and 21.5 dpc (term gestation,
22 days), weighed on a precision balance (SBC 21; Scaltec
Instruments, Heeligeesdadt, Germany), and killed by
decapitation. To evaluate newborn rats, the gestation was
continued in some pregnant rats until 22 dpc, and rats were
allowed to deliver spontaneously. Newborns rats were
harvested immediately after death or electively killed, by
decapitation, at 6 hours after delivery. In this regard, it might
be emphasized that all CDH pups died before our set point.
After weighing pups, laparotomy was performed under
binocular surgical microscopy (Wild M651.MS-D; Leica,
Herbrugg, Switzerland) to inspect the diaphragm. Hearts
were excised en bloc through median sternotomy. Myocar-
dial samples were harvested from LV and RV free wall and
snap-frozen at −80° for further molecular studies. Fetuses
were assigned to the following 3 experimental groups:
(i) control group—fetuses or pups exposed to olive oil alone,
without CDH; (ii) nitrofen group—fetuses or pups exposed
to nitrofen without CDH; and (iii) CDH group—fetuses or
pups exposed to nitrofen with CDH. Fetuses and pups with
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structural cardiac defects were excluded. Because it was not
feasible to accurately identify a diaphragmatic defect at 15.5
dpc, only 2 groups were defined: control and nitrofen
(exposed to nitrofen with or without CDH).
1.2. Molecular studies
1.2.1. Ribonucleic acid extraction and
reverse transcription
Total mRNA from LV and RV samples of 150 fetuses
(n = 10 each for control, nitrofen, and CDH, in each studied
time-point: 15.5 dpc, 17.5 dpc, 19.5 dpc, 21.5 dpc, and
newborn) was extracted using the RNeasy Mini Kit
Protect (74712; Qiagen, Germany). Quantification of total
mRNA was done by spectrophotometry (BioPhotometer,
Eppendorf, Germany), and the A260/A280 ratio was used
to test protein and deoxyribonucleic contamination of the
extracted product.
Reverse transcription was performed as previously
described by Santos et al [34].
1.2.2. Quantitative polymerase chain reaction
Quantitative real-time polymerase chain reaction was
performed as previously described by Santos et al [34].
Primer design was based on the available sequences in
GenBank (NCBI-NLM-PubMed-Gene). All the primers are
intron spanning (Table 1). For all the primer sets, standard
amplification curves (ST curves) were made with randomly
selected complementary DNA samples, setting r = 0.99. In
every quantitative run, 3 replicas of the standard ST-100 ng
were included as internal controls and quantitative references
for the variability of the procedure. The samples gene's
expression was normalized for β-actin.
1.3. Statistical analysis
Results were presented as mean ± SEM. Statistical
analysis was performed using the SigmaStat 3.5 software.
The different data sets of control, nitrofen, and CDH groups
failed in the Kolmogorov-Smirnov test for normality.
Therefore, statistical analysis was performed by the 1-way
analysis of variance on ranks and the Dunn test for posttest
analysis. Statistical significance was set at P b .05.UNTable 1 Primers used for quantitative polymerase chain reactionGene Accession no. Primer set
BNP NM_031545 5′-GCA GAA GCT
5′-GCT GTC TTG A
Angiotensinogen NM_134432 5′-GGATAAGTCCA
5′-CAGACACCCCT
ET-1 NM_012548 5′-CAGAAACAGC
5′-GGAGGAGCAG
β-actin NM_031144 5′-GAT TTG GCA C
5′-ACT TTG GTC ATE
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12. Results
1The mRNA levels of BNP, angiotensinogen, and ET-1
1(through gestation, in the RV and LV, in the control, nitrofen,
1and CDH groups) are presented in Figs. 1–3, respectively.
1The BNP mRNA expression in the RV demonstrated in
1control group a significant decrease of around 19.5 dpc,
1followed by a peak increase at 21.5 dpc. After birth, its levels
2are similar to earlier studied stages of heart development. In
2comparison with the control group, we found significant
2differences both in nitrofen and CDH groups, characterized by
2a mirror-image pattern of expression, with inverse peak
2increase at 19.5 dpc and a subsequent decrease at 21.5 dpc.
2After birth, the BNP mRNA expression in RV was similar in
2the nitrofen and control groups, but in the CDH group, we
2found a significant increase in its expression (5.5-fold) (Fig. 1).
2The BNP mRNA expression in LV revealed a similar
2expression pattern in all study groups during fetal develop-
2ment. The control group had a significant decrease of around
219.5 dpc followed by an increase at 21.5 dpc, although its
2magnitude was not as evident as occurred in the RV.
2Regarding the nitrofen and CDH groups, we also found a
2mirror-image pattern of expression. Nevertheless, after birth,
2the levels of BNP mRNAwere similar to prior stages of heart
2development in the 3 groups (Fig. 1).
2Concerning the expression of angiotensinogen mRNA in
2the RV, we observed a slight increase from 17.5 dpc that
2peaked at 19.5 dpc, followed by a decrease to basal levels at
221.5 dpc. After birth, its levels remained constant. In the
2nitrofen and CDH groups, there was no significant variation
2in angiotensinogen mRNA expression through gestation. At
2birth, a significant rise occurred in the CDH group, compared
2with the control and nitrofen groups (Fig. 2).
2Similar to the expression of BNP, in the control group, we
2found an LV angiotensinogen mRNA expression pattern
2similar to RV. Its expression rose from 17.5 dpc, peaked at
219.5 dpc, then slowly decreased until birth. Regarding the
2nitrofen and CDH groups, angiotensinogen mRNA levels in
2LV did not vary during gestation and after birth (Fig. 2).
2In the control group, ET-1 mRNA level in RV showed a
2significant peak of expression at 19.5 dpc, followed by a
2constant level of expression that persisted even after birth.
2During fetal development, both the nitrofen and CDH groupsProduct size (base pair)
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ig. 2 Expression of angiotensinogen mRNA from 15.5 dpc to
hours of postnatal life in control, nitrofen, and CDH fetuses, both
RV (upper) and LV (bottom). *P b .05 vs control group; ξP b .05
6 dpc.
Fig. 1 Expression of BNP mRNA from 15.5 dpc to 6 hours of
postnatal life in control, nitrofen, andCDH fetuses, both inRV (upper)
and LV (bottom). *P b .05 vs control group; ξP b .05 vs 16 dpc.
4 M.J. Baptista et al.
ARTICLE IN PRESSUN
CO
RR
Ehad exactly the same expression pattern, without any
significant difference from control. However, after birth,
whereas in the nitrofen group, we did not found any
difference from the control group, the CDH group had a
significant increase in ET-1 mRNA expression (Fig. 3).
Finally, the LV the expression of ET-1 mRNA showed a
peak at 21.5 dpc and returned to baseline levels after birth. In
the nitrofen and CDH groups, we found the same pattern of
expression of the gene, without any difference compared
with the control group (Fig. 3).
To evaluate the relative expression changes of mRNA of
studied genes in the LV and RV after birth, we used the RV-
to-LV mRNA ratio (Fig. 4). In the control group, mRNA of
the 3 genes had similar relative expression in both ventricles.
On the other hand, in the CDH group, we found a very
significant increase in the RV-to-LV ratio expression patterns
of BNP, angiotensinogen, and ET-1.
3. Discussion
In this study, we determined the cardiac expression of
BNP, angiotensinogen, and ET-1 mRNA during perinatalOO
F
development in normal and nitrofen-exposed rats. Cardiac
expression of these genes showed temporal changes,
suggesting a closely regulated developmental expression.
Our results also showed late fetal cardiovascular disturbances
in nitrofen-exposed fetuses. Moreover, it clearly illustrates
that CDH pups, in early postnatal adaptation, experience
severe RV molecular adaptation to pressure overload.
In our day, CDH remains a challenge in perinatology.
The most severely affected babies have an extremely high
mortality rate despite aggressive treatment. Persistent
hypoxia because of pulmonary hypoplasia and hypertension
is considered by several authors as the main problem in
CDH. Nevertheless, centers without extracorporeal mem-
brane oxygenation did not significantly improve the
outcome using techniques targeted to lung-dependent
oxygenation, such as high-frequency ventilation or pulmon-
ary vasodilator therapy. Although the real significance of PH
is not completely defined in infants with CDH, it is well
known that severe PH is associated with increased mortalityF
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ig. 4 Right ventricle–to–LV mRNA ratio of BNP, angiotensi-
ogen, and ET-1 in control and CDH groups at 6 hours after birth.
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Fig. 3 Expression of ET-1 mRNA from 15.5 dpc to 6 hours of
postnatal life in control, nitrofen, and CDH fetuses, both in RV
(upper) and LV (bottom). *P b .05 vs control group; ξP b .05 vs
16 dpc.
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[35]. Pulmonary hypertension interferes with gas exchange
as well as hampers myocardial performance, with addi-
tional compromise of pulmonary blood flow and tissue
oxygenation [36].
From fetal to adult life, cardiopulmonary interaction plays
a significant role in physiologic hemodynamics. Pathologic
conditions affecting the lung or the heart could hamper this
equilibrium. Although the pulmonary consequences of
cardiac disease are well recognized, the influences of
pulmonary changes on cardiac function are less well
appreciated, particularly in fetuses. In late fetal life, several
physiologic hemodynamic changes occur, such as initiation
of ductus arteriosus closure and pulmonary vasodilatation, as
well as increase in RV output to the pulmonary artery [37].
These modifications are promoted by many paracrine
factors, among which systems such as natriuretic peptides,
angiotensin, and ET-1 are supposed to play a role in different
stages of heart development. Although significant alterations
in these systems are well documented in pressure and volume
cardiac overload in adults, the exact expression pattern of
these genes in relation to fetal cardiac load was not
previously defined. In our study, we demonstrated aTE
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3distinctive cardiac expression pattern of these genes during
3normal perinatal fetal rat development, presumably related to
3hemodynamic variations.
3Endothelin 1 mRNA expression is different in the LVand
3RV, probably because of different loads in the LV and RV.
3This gene has a peak expression at 19.5 dpc in the RV,
3whereas in the LV, this occurs at 21.5 dpc. On the other hand,
3angiotensinogen and BNP have a very similar expression
3pattern in the RV and LV but a mirror expression compared
3with each other. We established that, in both ventricles, when
3BNP increases, angiotensinogen decreases. The opposed
3effect of natriuretic peptides and angiotensin in myocardium
3as well as in vessels is well known. Generally, BNP has
3potent inhibitory effects on the renin-angiotensin-aldoster-
3one system [38], and in heart failure, activation of the renin-
3angiotensin-aldosterone system is suppressed by BNP [39].
3These systems might form an important regulatory complex
3of fetal vascular physiology and development. Hypotheti-
3cally, dysregulation of these delicate control mechanisms
3could interfere with the cardiopulmonary hemodynamics and
3lead to disease.
3Pulmonary vascular abnormalities in CDH have been well
3described from early stages of lung development. They
3consist of fewer pulmonary arteries per unit lung volume and
3peripheral muscularization of small arteries with medial and
3adventitial thickening [8]. Although the underlying mechan-
3isms are not completely understood, these anomalies may
3cause abnormal vascular reactivity, and CDH lungs may
3become unable to adapt normally at birth [40]. The
3importance of abnormal vascular development as a determi-
3nant of survival in CDH has just recently been appreciated.
3Nonetheless, we are far from understanding the specific
3interplay of the factors regulating vascular tone in CDH as
3well as the significance of those anomalies during fetal heart
3and lung development.
3In our work, we intended to define the fetal and neonatal
3expression pattern of 3 genes related to ventricular pressureF
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load in the nitrofen rat model of CDH. We demonstrated that
during late fetal life, the nitrofen-exposed fetuses had
significant variations in heart expression of mRNA BNP
and angiotensinogen, evocative of cardiovascular distur-
bances. Remarkably, the mirror expression pattern of these
2 genes observed in control rat fetuses is preserved in
nitrofen-exposed fetuses. Nevertheless, there are no altera-
tions in ET-1 mRNA cardiac expression, and the variation
reported in angiotensinogen and BNP genes occurred both in
CDH and non-CDH nitrofen–exposed fetuses. These results
suggest that the abnormalities observed are probably
consequence of nitrofen action and not related to a
hypothetical pulmonary vascular remodeling. We believe
that, as occurs in several congenital malformations, PH in
CDH is balanced during fetal life and should not have
hemodynamic consequences or induce cardiac adaptation. In
fact, pulmonary vascular remodeling, when present, should
not cause elevated RV pressures in the fetus given the
presence of the ductus arteriosus.
In infants with CDH, intrauterine pulmonary hypoplasia
and vascular remodeling may cause failure of pulmonary
vascular resistance to fall at birth. This event implies an
increased pressure overload to RV, with additional wall and
endothelium stress, responsible for the initiation of cardiac
adaptation. Several studies suggest that in PH, the LV
experiences both systolic and diastolic function adaptation
because of bulging of the ventricular septum and diminished
RV output [41]. In our study, the increased levels of all
studied cardiac pressure overload markers in the RVof CDH
pups after birth may indicate increased pulmonary vascular
resistance in the CDH group. This response is specific for
RV, and in this model, we did not demonstrate any LV
molecular adaptation to PH.
In conclusion, perinatal myocardial quantification of
BNP, ET-1, and angiotensinogen mRNA demonstrated that
CDH is associated with significant molecular adaptation only
in RV after birth. In fact, although nitrofen induced a
hemodynamic imbalance in the expression of these genes,
the major and novel observation from our work is the
absence of cardiac impact of PH during late fetal life.O 481
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and to compare our findings with those of Miele et al, which used
similar diagnostic criteria and study design. I believe that exam-
ining differences in the clinical course of infantile regurgitation
between different ethnic groups as mentioned here will be bene-
ficial for understanding the nature of GER in children in general.
Seksit Osatakul, MD
Department of Pediatrics
Prince of Songkla University
Hat-Yai, Songkhla 90110, Thailand
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In Reply.—
We thank Dr Osatakul for his thoughtful comments. By the
comparison of our and his data, it seems that the natural course of
infant regurgitation, diagnosed on the basis of the Rome diagnos-
tic criteria,1 in Italian infants is slightly different from that in Thai
subjects. In fact, this functional disorder seems to persist in Italian
subjects for a longer time during the 1-year follow-up despite a
larger use of antiregurgitation drugs. The reasons for these differ-
ences are not known, but they may indicate both genetic and
environmental factors peculiar to these particular racial groups.
As suggested by Osatakul et al,2 the variation in gastroesophageal
reflux (GER)-related genomes could play a role in the differences
in epidemiology among different groups. Recent reports have
suggested that both pediatric and adult-onset GER have major
genetic components.3,4 In a recent study, a clear relationship be-
tween maternal symptoms of GER and symptoms of spilling in
infancy and middle-childhood GER has been found, suggesting
that genetic factors are important in milder GER.4 In addition, in
adult Chinese subjects, it has been demonstrated that most of the
factors involved in the pathogenesis of GER disease, previously
described in Western studies, are present but at lower scale.5 The
acidity of gastric contents is reduced spontaneously or by Helico-
bacter pylori infection. A low-fat diet contributes to a more favor-
able gastric distribution of the meals and reduced obesity and
lowers the number of transient lower esophageal relaxations. The
prevalence of hiatal hernia is low and esophageal motility disor-
ders are moderate. Some of these factors could be responsible for
the differences in the prevalence and in the natural course of the
infant regurgitation in Western and non-Western infants as well.
In conclusion, the role of several interesting and important factors
needs to be clarified with additional cross-cultural genetic and
environmental studies.
Erasmo Miele, MD
Annamaria Staiano, MD
Department of Pediatrics
University of Naples “Federico II”
80131 Naples, Italy
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Brain-Type Natriuretic Peptide in the Diagnosis
and Management of Persistent Pulmonary
Hypertension of the Newborn
To the Editor.—
We read with great interest “Brain-Type Natriuretic Peptide in
the Diagnosis and Management of Persistent Pulmonary Hyper-
tension of the Newborn” by Reynolds et al.1 The authors suggest
the blood level of brain-type natriuretic peptide (BNP) as a marker
that can be used as an adjunct parameter to differentiate newborns
with persistent pulmonary hypertension from other noncardiac
causes of respiratory distress. This information might be particu-
larly useful in deciding appropriate treatment and planning early
transfer to centers with echocardiographic facilities. Although hy-
pothesized in their discussion, the study by Reynolds et al did not
investigate if cardiac anomalies resulting in ventricular stress in
neonates might also induce elevated blood levels of BNP. It is
worth clarifying this aspect, because these patients could require a
different therapeutic approach than infants with persistent pul-
monary hypertension.
It is interesting to note that we currently are performing a
clinical study aimed at assessing the clinical value of BNP mea-
surements in newborns with congenital heart disease that results
in pressure overload to the right ventricle. In this setting, we
already studied 7 newborns that required catheterization with
therapeutic purpose (1 with pulmonary atresia with intact ven-
tricular septum and 6 with critical pulmonary stenosis). None of
them had other morphologic or chromosomal anomalies. All the
newborns revealed echocardiographic signs of right ventricular
pressure overload, with significant tricuspid regurgitation, right-
to-left interauricular shunting, and high estimated right ventricu-
lar pressure/mean blood pressure ratio (2:3). Measurement of
BNP level was performed in venous blood samples collected from
femoral vein before contrast injection. None of these newborns
were submitted to cardiac catheterization without a clinical pur-
pose, and no additional blood was required. In this preliminary
study, we found a significantly high value of BNP (2500 pg/mL)
in all patients. Additionally, we found a positive and significant
correlation between BNP levels and systolic right ventricular pres-
sure (r  0.81; P  .05) as well as to the mean right ventricular
pressure (r  0.77; P  .05).
In conclusion, our preliminary results confirm the suspicion
from Reynolds et al that cardiac anomalies such as pulmonary
stenosis/atresia might also result in elevated blood levels of BNP,
which correlated with right ventricular pressures. We believe,
therefore, that the blood level of BNP reflects ventricular stress,
and its elevation should be a criterion for prompt additional
evaluation but not necessarily an indication for beginning any
specific therapy directed at persistent pulmonary hypertension.
Maria Joa˜o Baptista, MD
Pediatric Cardiology
Jorge Correia-Pinto, MD, PhD
Pediatric Surgery
Gustavo Rocha, MD
Neonatology
Herci´lia Guimara˜es, MD, PhD
Neonatology
Jose´ Carlos Areias, MD, PhD
Pediatric Cardiology
Hospital Sa˜o Joa˜o
4200 Porto, Portugal
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In Reply.—
I thank Baptista et al for their interest in my research. In the
article, my co-workers and I1 hypothesized that brain-type natri-
uretic peptide (BNP) levels would be elevated in any pathologic
condition that resulted in abnormal stress on the ventricles. This
would be true of some, but not all, forms of congenital heart
disease. It seems from the preliminary data that the doctors are on
their way to confirming that hypothesis.
We excluded infants with congenital heart disease from our
study because of potential limitations of using the BNP assay in
this setting that occurred to us while planning for this project.
First, BNP is a marker for ventricular stress. It is not specific to any
particular disease state. Although BNP is elevated in infants with
persistent pulmonary hypertension (PPHN), it can also be ex-
pected to be elevated in any infant with congenital heart disease
that results in a state of ventricular stress. Second, low levels of
BNP, while suggestive of no ventricular stress, do not rule out
serious (potentially life-threatening) cardiac or respiratory dis-
eases.
As we concluded in the article, “the results of this study should
not be interpreted as showing that BNP levels are diagnostic of
PPHN or that measuring BNP levels can be used in place of
echocardiography.” It is unfortunate that not all practicing pedi-
atricians or neonatologists have access to 24-hour/7-day-a-week
echocardiography services. Serum BNP level is a useful adjuvant
diagnostic tool that can be used in conjunction with a thorough
physical examination, blood gas analysis, and other information to
help physicians determine the proper treatment for the patient.
Again, we emphasize that “[p]hysicians should have increased
suspicion of PPHN, or other states of ventricular stress, when
caring for a term or near-term newborn with RD [respiratory
distress] and an elevated BNP level.”
We feel that any infant with respiratory distress and an ele-
vated BNP level should receive a thorough evaluation, likely
including echocardiography, to determine the proper course of
treatment. We are glad that preliminary data from Baptista et al
support our hypothesis and that they agree with the conclusions
we put forth in our article. We look forward to their final manu-
script.
Eric W. Reynolds, MD
Department of Pediatrics
Division of Neonatology
University of Kentucky College of Medicine
Lexington, KY 40536
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Detection of the Bartonella henselae Gene
Sequence in Lymph Nodes of Children With
Kikuchi’s Disease
To the Editor.—
Kikuchi’s disease (KD), also known as Kikuchi-Fujimoto dis-
ease or histiocytic necrotizing lymphadenitis, was first described
in 1972 independently by Kikuchi1 and Fujimoto et al.2 Viral
infection has been suggested as a possible etiology because of
clinical manifestations such as fever, lymphadenopathy with a
self-limited course, and occasional peripheral lymphocytosis.
However, most studies failed to detect suspicious viral agents
including Epstein-Barr virus, human herpesvirus 8, human her-
pesvirus 6, and parvovirus B19 in KD.3 Some bacterial agents
including Yersinia enterocolitica, Toxoplasma, and Brucella were oc-
casionally identified by serologic methods.3 Although KD is rare
in children, it should be considered in the differential diagnosis of
infections, collagen diseases, or malignancy. Cat-scratch disease
(CSD) is a worldwide zoonosis caused by Bartonella henselae or
Bartonella clarridgeiae and is characterized by a self-limiting re-
gional lymphadenopathy associated with a cat scratch or bite.
However, no history of animal contact can be elicited in a small
percentage of patients with CSD. Atypical CSD is reported in up
to 25% of cases. CSD is usually suspected clinically and confirmed
by the detection of Bartonella DNA in lymph nodes by polymerase
chain reaction (PCR). We investigated the presence of B henselae
DNA in children diagnosed with KD. Twenty children who were
diagnosed with KD at Sanggye-Paik Hospital, Inje University
College of Medicine, from January 1998 to December 2004 were
included in the study. DNA was extracted from lymph node
specimens on slides and paraffin-embedded tissues. B henselae
strain Houston was used for a positive control, and 2 different
primers were used in this study. The PCR assay was performed by
using the citrate synthetase (gltA) gene, an outer pair of primers
consisting of TN-1 and TN-2, and an inner primer as described.4
Seminested PCR protocols for amplification of the pap31 gene of B
henselae with primers PAPn1, PAPn2, and PAPns2 were as de-
scribed.5 The PCR products were separated by electrophoresis on
1.5% agarose gels and visualized by staining with ethidium bro-
mide. PCR products were sequenced in both directions, and se-
quence analysis was performed. The mean age of the 20 children
with KD was 13 years (range: 5–17 years). Eleven patients were
female. The lymph node lesions were located in the cervical area
in 80% of the children, the submandibular area in 10%, and the
axillary area in 5%. B henselae DNA was detected in 4 patients
(25%). With the gltA primer, a positive PCR result was obtained
from 4 patients (25%), whereas the pap31 primer amplified B
henselae DNA in only 1 patient (5%). The amplification products
were confirmed by sequence analysis. None of the negative con-
trols were positive. We had performed seminested PCR assays by
using different primers targeting the citrate synthetase (gltA) gene
and pap31 gene of B henselae in lymph nodes of children with KD.
A diagnosis of CSD by PCR from fine-needle aspiration and
primary lesion specimens was reported to be minimally invasive
and highly accurate.6 Typical pathologic findings are characteris-
tic of, but not specific for, CSD. The results of our study suggest
that B henselae may be an etiologic agent in some children diag-
nosed with KD. Additional studies are needed to clarify the asso-
ciation of B henselae with KD.
Ju-Young Chung, MD
Department of Pediatrics
Sang Woo Kim, MD
Department of Pediatrics
Tae Hee Han, MD
Department of Diagnostic Laboratory Medicine
Sung Jig Lim, MD
Department of Pathology
Sanggye-Paik Hospital
Inje University College of Medicine
763-1, Sanggye 7-Dong, Nowon-gu, Seoul 139-707,
Korea
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ly correlated with estimated pulmonary artery pressure, 
right ventricular Tei index, and tricuspid E/A ratio. Addition-
ally, we found that CDH infants with NT-proBNP  1 11,500 pg/
ml experienced a worse prognosis.  Conclusions: We dem-
onstrated that PH is associated with NT-proBNP elevation 
and diastolic impairment in CDH infants. Early elevations in 
NT-proBNP levels seem to alert for a subset of CDH infants 
with worse prognosis.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Despite many advances in the management of con-
genital diaphragmatic hernia (CDH), the outcome of af-
fected infants remains unpredictable and varies from 
year to year even in experienced teams with predeter-
mined treatment protocols. Its morbidity and mortality 
is largely dependent of pulmonary hypertension (PH) 
and hypoplasia  [1] . Pulmonary hypoplasia installs during 
prenatal development  [2–4] and limited possibilities exist 
to attenuate it  [5, 6] . PH is likely secondary to pulmonary 
 Key Words 
 N-terminal-pro-B type natriuretic peptide   Congenital 
diaphragmatic hernia   Pulmonary hypertension   
Cardiac function   Diastole 
 Abstract 
 Objective: In congenital diaphragmatic hernia (CDH) the se-
verity of pulmonary hypertension (PH) is considered, by sev-
eral authors, determinant of clinical outcome. Plasmatic N-
terminal-pro-B type natriuretic peptide (NT-proBNP) might 
be useful in diagnosis and management of PH in newborns, 
although its interest in CDH infants remains to be defined. 
Early NT-proBNP levels were assessed in CDH infants and 
correlated with cardiovascular echocardiographic parame-
ters.  Patients and Methods: 28 newborns, CDH and age-
matched controls were enrolled in a prospective study. Clin-
ical condition, NT-proBNP plasmatic levels, echo parameters 
of PH and biventricular function were assessed at 24 h after 
delivery as well as survival outcome.  Results: Estimated 
mean pulmonary pressure and NT-proBNP were significant-
ly higher in CDH than control infants. NT-proBNP significant-
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hypoplasia and associated underdeveloped vascular bed, 
which for some authors is a major determinant of post-
natal clinical outcome  [7] . For this reason, evaluation of 
PH severity is considered important for management of 
CDH infants in several centers  [1] and its assessment is 
crucial to decide upon pulmonary vasodilator therapy as 
well as to monitor its effects  [8, 9] . Furthermore, for these 
authors the decision for surgical repair should be based 
on evidence of PH stabilization  [10] . Assessment of PH is 
mainly based on clinical and echocardiographic estima-
tion. However, echocardiographic evaluation is not al-
ways available and it is somewhat observer-dependent 
and technically demanding in CDH infants due to the 
presence of abdominal organs in thoracic cavity. An easy 
and reliable method to assess PH remains to be defined. 
On the other hand, PH could induce cardiac dysfunction 
due to right ventricular (RV) overload, although this as-
pect has not been clearly elucidated in CDH infants  [11] .
 B-type natriuretic peptide (BNP) is a hormone of pre-
dominantly ventricular origin produced and released in 
response to increased ventricular wall stress  [12, 13] . N-
terminal-pro-BNP (NT-proBNP), the amino-terminal 
portion of the preprohormone, is secreted into the pe-
ripheral blood in equimolar portions to BNP, but it has 
a longer half-life and is easier to measure  [13] . In recent 
years, NT-proBNP has emerged as a very sensitive bio-
chemical marker for ventricular dysfunction in adult 
heart failure, the plasmatic level of which could be used 
as a guide for the response to therapy and to predict 
prognosis  [14] . However, in children the knowledge 
about the significance of plasma levels of NT-proBNP is 
still limited. In healthy children, studies have shown 
that NT-proBNP levels are elevated soon after birth 
reaching its peak at 24 h of life decreasing thereafter up 
to 4 months and remaining unchanged until the age
of 15  [15–19] . NT-proBNP levels are elevated in chil-
dren with congenital heart disease or cardiomyopathy 
 [20–22] . In infants, it was also demonstrated that NT-
proBNP is elevated in symptomatic patent ductus arte-
riosus in preterms  [23, 24] and PH  [25] . Additionally, in 
newborns submitted to cardiac catheterization due to 
critical pulmonary stenosis or atresia, NT-proBNP cor-
relates with hemodynamic measured RV pressure  [26] . 
However, assessment of plasmatic NT-proBNP and its 
clinical usefulness in newborns with PH due to CDH 
remains to be defined.
 The aim of this study was to compare echocardio-
graphic parameters of cardiac function and plasmatic 
NT-proBNP levels, at 24 h after birth, between CDH and 
healthy infants.
 Materials and Methods 
 Study Subjects 
 From January 2004 to October 2006, we enrolled in this study 
term or near-term newborns ( 6 36 weeks’ gestation) admitted to 
our hospital’s neonatal intensive care unit (NICU) or normal 
newborn nursery. Two groups were defined: (1) a control group 
that included healthy infants, and (2) a CDH group that  included 
consecutive newborns with left-sided CDH (Bochdalek hernia) 
without heart defect. Sample size was calculated in order to detect 
a difference of at least 2 units between groups’ means, assuming 
a standard deviation of 1 unit, with a 95% confidence level (5%   
level) and at least 85% power, in an independent samples Student’s 
t test. Thus, we estimated having to recruit at least 20 newborns 
(10 CDH patients and 10 controls).
 Healthy infants were identified from patients that needed 
blood sampling, at the second day of life, for clinical reasons not 
related to this study, specifically by suspected sepsis or physiolog-
ic jaundice. In these infants, echocardiography was performed 
immediately before blood was drawn for functional evaluation 
and exclusion of congenital heart disease. Physiologic jaundice is 
defined as a benign condition with bilirubin levels  ! 15 mg/day. 
Infants with confirmed sepsis or newborns with transient tachy-
pnea as well as congenital heart disease, PH or hemodynamic sig-
nificant ductus arteriosus were excluded from this study.
 In CDH newborns, echocardiography was done immediately 
before blood was drawn that is performed routinely at 24 h of life. 
Clinical management of CDH infants in our NICU include de-
layed surgical repair after extensive preoperative stabilization 
with ‘gentle ventilation’ and inhaled nitric oxide treatment, if
necessary. We could not manage patients with extracorporeal 
membrane oxygenation (ECMO) since it is not available in our 
center.
 NT-proBNP was measured in the blood drawn in these two 
groups.
 Demographic data from both study groups included postmen-
strual age at delivery, gender, birth weight as well as 1- and 5-min 
Apgar scores. At the moment of blood sampling, data gathered 
included systolic, mean and diastolic blood pressure, requirement 
of inotropic support, pulmonary vasodilator therapy as well as of 
mechanical ventilation, current ventilator settings and blood gas-
es. In CDH infants the oxygenation index and the ventilatory in-
dex were calculated. Simultaneously, echocardiographic param-
eters and plasmatic NT-proBNP levels were recorded. Addition-
ally, we recorded the day of surgery as well as survival taking into 
account that survivor newborn was defined as alive at discharge 
from NICU.
 The study was approved by the Institutional Review Board of 
our hospital and informed consent was obtained from the parents 
of all participants. No infant, neither case nor control, received 
additional blood collection, other than routine blood sampling, 
as a consequence of this study, as NT-proBNP usually could be 
measured in the routine amount of blood sample. Data collected 
from this study were not used to influence medical decision-mak-
ing. Management of each infant was left to the criteria of the at-
tending physician, according to the treatment protocol of our 
NICU. NT-proBNP plasmatic measurement was not achieved in 
5 CDH newborns, due to insufficient sample.
 Baptista et al.
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 Echocardiographic Assessment 
 The echocardiographic assessment was designed as part of the 
infants’ routine care or additionally to that, at no cost to the pa-
tient. All examinations were performed with an echograph Aloka 
(Tokyo, Japan) using a 5-MHz probe, by the same investigator 
(M.J.B.). Once echocardiography always preceded blood sam-
pling, the investigator interpreting echocardiography was blind-
ed to NT-proBNP levels, although not blinded for control versus 
CDH groups.
 In infants from control and CDH groups, echocardiography 
was performed to exclude congenital heart disease and to ascer-
tain the following parameters: (i) RV and left ventricular (LV) 
systolic and end-diastolic dimensions (M-mode, parasternal ven-
tricular short-axis view); (ii) mitral and tricuspid diastolic dimen-
sions (2D, 4-chamber view); (iii) dimensions of the right and left 
pulmonary arteries (RPA and LPA); (iv) orientation of ventricular 
septum (existence of bulging to left ventricle); (v) ductus arterio-
sus and foramen oval patency and shunt direction; (vi) existence 
and quantification of tricuspid regurgitation as well as RV-right 
atrium (RA) gradient; (vii) RV outflow acceleration time (OAT); 
(viii) RV outflow ejection time; (ix) peak flow velocity of A and E 
wave at mitral and tricuspid valves; (x) time from cessation of tri-
cuspid and mitral inflow to onset of tricuspid and mitral inflow, 
respectively, in the next cardiac cycle. These allowed the estima-
tion of: (xi) mitral-to-tricuspid ratio; (xii) LPA-to-RPA ratio; (xiii) 
estimated right ventricular systolic pressure (RVSP) through the 
formula: RVSP = tricuspid regurgitation gradient + RA pressure, 
assuming a normal RA pressure of 4 mm Hg  [27, 28] ; (xiv) esti-
mated mean pulmonary artery pressure (MPAP), through the for-
mula MPAP = 90 – (0.62  ! OAT)  [29] ; (xv) tricuspid and mitral 
E/A ratios; (xvi) the RV and LV Tei index, as described by Tei et 
al.  [30] , assessed as Tei index = (time from cessation of tricuspid 
or mitral inflow to onset of tricuspid or mitral inflow in the next 
cardiac cycle – RV or LV outflow ejection time)/RV or LV outflow 
ejection time; (xvii) RV OAT to RV outflow ejection time, a quan-
titative predictor of peak PA pressure in infants  [31] . Measure-
ments were obtained in 3 consecutive cardiac cycles and averaged 
to account for respiratory variation.
 Taking into account the distinct characteristics of RV and LV, 
we evaluate ventricular function using different parameters: (i) 
global function, using the Tei index in RV and LV  [32] ; (ii) sys-
tolic function, with peak pulmonary flow velocity in RV  [33] and 
ejection fraction in LV; (iii) diastolic function, tricuspid and mi-
tral E/A ratio in RV and LV, respectively.
 In CDH newborns the echocardiographic window is limited 
due to the intrathoracic position of abdominal organs and me-
chanical ventilation. Nevertheless, the echocardiographic proto-
col was completed in all CDH patients. For that purpose the sub-
costal window or right-sided parasternal window was sometimes 
used instead of the classical echo windows.
 NT-proBNP Measurement 
 The plasmatic level of NT-proBNP was evaluated at 24 h of life 
in every control infant and in 13 of the 18 CDH patients. NT-
proBNP levels were measured with a chemiluminescent immuno-
assay kit (Roche Diagnostics, Portugal) on an Elecsys 2010 ana-
lyzer. Venous blood samples were collected in EDTA-containing 
tubes.
 Statistical Analysis 
 Descriptive statistics were presented as mean and standard de-
viation as appropriate. Plasma NT-proBNP measurements resem-
bled a log-normal distribution, so natural logarithmic transfor-
mation was used to normalize the distribution when indicated. 
Comparisons between groups were performed using Fisher’s ex-
act test for categorical variables. For continuous variables com-
parisons, we used Student’s t test if normality of the distributions 
could be assumed or non-parametric Mann-Whitney U test if 
normality could not be assumed. In order to test the normality of 
the distribution of the continuous variables the one-sample Kol-
mogorov-Smirnov goodness-of-fit test was applied. Pearson cor-
relation coefficients were calculated to evaluate the relationship 
between NT-proBNP and estimated pulmonary pressure as well 
as the echocardiographic parameters of cardiac function. To de-
scribe the discriminative power of plasma NT-proBNP measure-
ment concerning mortality outcome, sensitivity and specificity 
were calculated for various levels of this variable, a receiver oper-
ating characteristic (ROC) curve was drawn. Given the small 
sample size it was not possible to analyze the prognostic value of 
plasma NT-proBNP measurements using appropriate multivari-
ate modeling methods. For hypothesis testing, a value of p  ! 0.05 
was considered significant.
 Results 
 In this study, we evaluated 28 infants, 10 in the control 
group and 18 in the CDH group. In the CDH group, NT-
proBNP was evaluated only in 13 newborns, due to an 
insufficient amount of blood for the measurement. The 
demographic data of CDH infants are presented in  ta-
ble 1 . Excluding Apgar scores in CDH infants, no signif-
icant differences were identified with regards to birth 
weight, gestational age and gender.
 The clinical conditions of CDH newborns, regarding 
the requirement of inotropic support, pulmonary vaso-
dilator therapy as well as day of surgery and outcome, 
are summarized in  table 2 . NT-proBNP levels were sig-
nificantly higher in CDH than in the control group 
( fig. 1 ).
 Evaluated echocardiographic parameters in control 
and CDH groups are presented in  table 3 . In newborns 
with CDH, estimated MPAPs were significantly higher 
when compared to the control group reflecting an in-
creased afterload to the RV. All newborns from CDH 
groups had some echocardiographic evidence of PH, 
bulging of interventricular septum and right-to-left shunt 
at the level of ductus arteriosus and foramen ovale. Mor-
phologically, RV systolic and diastolic dimensions were 
significantly higher in the CDH group than the control 
group, whereas LV systolic and diastolic dimensions were 
significantly lower in the CDH than the control group. 
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Additionally, mitral-to-tricuspid and LV-to-RV diastolic 
M-mode ratios were significantly lower in the CDH than 
the control group.
 Evaluation of global function parameters revealed 
that the RV Tei index was significantly higher in the CDH 
than the control group. Regarding systolic function, in 
comparison to the control group, CDH infants had a 
slightly depressed RV function as evidenced by a signifi-
cant decrease in peak pulmonary velocity, whilst the LV 
systolic function was enhanced as demonstrated by a 
higher LV ejection fraction. Both RV and LV diastolic pa-
rameters (E/A auriculo-ventricular ratios) were signifi-
Table 2. Clinical data of CDH newborns
Infant Inotropic support Vasodilator
therapy
Mechanical ventilation Day of
surgery
Day of
discharge
1 Yes (dopamine and dobutamine) Yes (iNO) SIMV (for 24 days) D14 D24 (death)
2 No No SIMV (for 10 days) D7 D14 (alive)
3 Yes (dopamine and dobutamine) No SIMV (for 2 days) No D2 (death)
4 Yes (dopamine and dobutamine) No SIMV (for 2 days) No D2 (death)
5 No No SIMV (for 6 days) D4 D13 (alive)
6 Yes (dopamine and dobutamine) No SIMV (for 12 days) D4 D18 (alive)
7 No No SIMV (for 6 days) D4 D11 (alive)
8 Yes (dopamine) No SIMV (for 7 days) D4 D24 (alive)
9 Yes (dopamine and dobutamine) No SIMV (for 3 days) D3 D3 (death)
10 No No SIMV (for 14 days) D5 D21 (alive)
11 Yes (dopamine and dobutamine) Yes (iNO) HFVO (for 89 days) D42 D89 (death)
12 Yes (dopamine and dobutamine) Yes (iNO) HFVO (for 20 days) D9 D38 (alive)
13 Yes (dopamine) No SIMV (for 7 days) D3 D17 (alive)
14 Yes (dopamine) Yes (iNO) SIMV (for 6 days) No D6 (death)
15 Yes (dobutamine) Yes (iNO) SIMV (for 35 days) D14 D46 (alive)
16 Yes (dopamine) Yes (iNO) SIMV (for 8 days) D8 D21 (death)
17 Yes (dopamine) Yes (iNO) SIMV (for 11 days) No D11 (death)
18 Yes (dopamine) Yes (iNO) SIMV (for 13 days) D4 D13 (death)
iNO = Inhaled nitric oxide; SIMV = synchronous intermittent mandatory ventilation; HFOV = high-frequency oscillatory ventila-
tion.
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 Fig. 1. Plasmatic NT-proBNP level is significantly increased in new-
borns with CDH compared to control ( * p  ! 0.05 vs. control). 
Table 1. Demographic data
Groups studied p value
control group
(n = 10)
CDH group
(n = 18)
Birth weight, g 3,2368612 2,9548451 0.1751
Gestational age, weeks 38.381.3 37.781.7 0.4301
Male gender 9 (90) 12 (67) 0.3642
1-min Apgar, median 9 7 0.0033
5-min Apgar, median 10 8 <0.0013
Hours of measurement 2681.2 2380.9 0.4631
CDH = Congenital diaphragmatic hernia. For continuous 
variables, values are expressed as numbers of infants (%) or means 
8 SD.
1 t test for independent samples. 2 Fisher’s exact test. 3 Mann-
Whitney non-parametric test.
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cantly lower in the CDH group than the control group, 
suggesting significant RV and LV diastolic impairment 
in the CDH group. We found significant correlations be-
tween NT-proBNP and estimated pulmonary mean pres-
sure (r = 0.45; p = 0.03), RV Tei index (r = –0.50; p = 0.02) 
and tricuspid E/A ratio (r = –0.46; p = 0.03).
 Comparison between Survivors and Non-Survivors 
 Nine infants of the CDH group died. A comparison 
between survivors and non-survivors is presented in  ta-
ble 4 . NT-proBNP plasmatic level, at the end of the first 
day of life, was significantly higher in non-survivor than 
in survivor newborns. There are no differences between 
both groups concerning birth weight, gestational age, 1- 
and 5-min Apgar or mean arterial blood pressure. Re-
garding pulmonary indices, we detected significant dif-
ferences between survivor and non-survivor infants. On 
echo parameters, we identified that estimated mean pul-
monary pressures were significantly higher in non-sur-
vivor than in survivor CDH infants, whereas pulmonary 
acceleration to ejection time and tricuspid E/A ratios 
were significant lower in non-survivor than in survivor 
CDH infants.
 The NT-proBNP level of 11,500 pg/ml was the value 
with highest specificity and sensitivity to separate survi-
vor and non-survivor CDH infants in ROC curves, in 
CDH infants. According to the ROC curve, the cutoff 
NT-proBNP level of 11,500 pg/ml has 100% sensitivity 
and 67% specificity. Infants with a plasmatic NT-proBNP 
at 24 h of life  1 11,500 pg/ml had a significantly lower sur-
vival rate than those with plasmatic NT-proBNP at 24 h 
of life  ! 11,500 pg/ml.
Table 3. Data of echocardiography in control and CDH infants at 24 h after birth
Control group CDH group pa
Pulmonary pressure
Pulmonary systolic pressure, mm Hgb – 56.0818.6
Pulmonary mean pressure, mm Hgb 41.6814.9 64.0814.9 0.001
Heart dimensions
Right ventricle
Tricuspid diameter, mm 9.4581.00 10.4582.00 0.055
RV systole M-mode, mm 5.7582.70 9.4084.70 0.017
RV diastole M-mode, mm 7.0082.15 11.3083.60 0.009
Left ventricle
Mitral diameter, mm 9.9081.80 8.1581.80 0.019
LV systole M-mode, mm 10.4081.10 7.9083.90 0.023
LV diastole M-mode, mm 16.0081.40 14.3083.50 0.025
Ratios
Mitral-to-tricuspid 1.0380.15 0.7980.15 <0.001
RPA-to-LPA 1.1580.30 1.1080.20 0.071
LV-to-RV diastole M-mode 2.3580.65 1.1080.40 0.002
Heart function
Global function
RV Tei index 0.2180.05 0.2880.09 0.002
LV Tei index 0.2280.17 0.2380.10 0.674
Systolic function
Peak pulmonary velocity, m/s 0.8080.18 0.5980.12 0.003
LV ejection fraction, % 6789 80817 0.02
Diastolic function
Tricuspid E/A ratio 0.9680.11 0.8080.13 <0.001
Mitral E/A ratio 1.0080.44 0.8180.13 0.019
Results are presented as median 8 interquartile range.
CDH = Congenital diaphragmatic hernia; RPA = right pulmonary artery; LPA = left pulmonary artery;
LV = left ventricle; RV = right ventricle.
a Mann-Whitney non-parametric test. b Both mean and systolic pulmonary pressure were estimated.
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 Discussion 
 In our study, we demonstrated that PH is associated 
with diastolic impairment and higher NT-proBNP levels 
measured at 24 h of life elevation in CDH infants. Early 
elevations in NT-proBNP levels seem to alert for a subset 
of CDH infants with worse prognosis.
 In recent years, PH has emerged for many authors as 
a key determinant of outcome in CDH infants  [1] . Con-
sequently, PH progressively becomes one of the therapeu-
tic targets in managing these newborns. In fact, in sev-
eral therapeutic approaches (delayed surgery, high-fre-
quency ventilation, nitric oxide inhalation, ECMO and 
other pulmonary vasodilators), one of the aims is con-
trolling PH, whereas the decision for surgical repair is 
based on evidence of PH stabilization  [9] . Since accurate 
evaluation of pulmonary artery pressure with a Swan-
Ganz catheter, in newborns, is not achievable, echocar-
diography is used to assess PH. Nevertheless, echocar-
diography is not available 24 h a day in all centers dealing 
with CDH infants and reliable parameters are not easy to 
quantify, most of them being observer-dependent. In this 
setting, non-invasive and examiner-independent param-
eters could be particularly useful to manage CDH infants 
with PH, but should be available in a short time frame 
 [34] .
 In this context, we investigated the potential signifi-
cance of plasmatic NT-proBNP levels in CDH infants. 
The elevated levels of NT-proBNP that we found in CDH 
infants should be secondary to PH. Previous studies have 
demonstrated both in adults  [35] and infants  [24] that 
plasmatic NT-proBNP levels are elevated in patients with 
Table 4. Parameters studied at 24 h of life in newborns with CDH according to survival
Survivors (n = 9) Non-survivors (n = 9) p
NT-proBNP, mg/ml 6,23084,743 22,65385,653 0.0092
log[NT-proBNP] * 8.7380.87 10.1480.30 0.0031
Demographic data
Birth weight, g * 3,0988415 2,8828620 0.2382
Gestational age, weeks * 3881.4 3782.5 0.6861
Male gender, n (%) 6 (67) 6 (67) 0.9993
1-min Apgar 881 783 0.212
5-min Apgar 981 883 0.1782
Mean arterial blood pressure, mm Hg * 4088 41810 0.4491
Pulmonary indices
PaO2 80820 42816 0.0032
PaCO2 46815 58816 0.0632
FiO2 0.380.6 1.080.0 0.0022
MAP 6.981.9 12.881.5 0.0032
Oxygenation index 2.285.0 28.8824.26 0.0032
Ventilatory index 2438141 8798139 0.0032
Echo indices
Mitral-to-tricuspid ratio 0.8280.20 0.7780.07 0.5962
LV-to-RV diastole M-mode ratio 1.281.0 1.180.2 0.4002
Pulmonary systolic pressure, mm Hg 42819 58819 0.0772
Pulmonary mean pressure, mm Hg 53811 6880.6 0.0092
RV Tei index 0.2780.05 0.3180.11 0.4112
LV Tei index 0.2280.09 0.2380.07 0.9992
Peak pulmonary velocity, m/s 0.5880.17 0.628011 0.7002
Pulmonary acceleration/ejection time 0.3380.1 0.2280.03 0.0022
Tricuspid E/A ratio 0.8580.11 0.7680.29 0.0202
Mitral E/A ratio 0.8280.15 0.7980.23 0.1912
Results are presented as median 8 interquartile range unless otherwise indicated. * mean 8 standard de-
viation.
1 t test. 2 Mann-Whitney non-parametric test. 3 Fisher’s exact test.
PaO2 = Oxygen arterial partial pressure; PaCO2 = carbon dioxide arterial partial pressure; MAP = mean 
airways pressure; LV = left ventricle; RV = right ventricle.
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PH. Although already demonstrated in adults, the cor-
relation between pulmonary artery pressure and NT-
proBNP has not previously been established in infants. In 
the present study we demonstrated that both in controls 
and CDH infants the plasmatic NT-proBNP level corre-
lates with estimated mean pulmonary pressure. In CDH 
infants, invasive measurement of pulmonary pressure 
and hemodynamic parameters of cardiac function is not 
feasible. Currently, magnetic resonance imaging is em-
ployed in children and adults to evaluate RV, but this is 
also not reasonable in critical CDH infants.
 We decided to measure the NT-proBNP at 24 h of life 
basically for two reasons: (1) it has been previously dem-
onstrated that NT-proBNP reaches its peak by the end 
of the first day of life in healthy infants  [15] , and (2) it is 
well known that a number of CDH infants do well dur-
ing the first day of life (‘honeymoon period’), but after 
this period the clinical status of the most severely af-
fected subset of CDH infants deteriorates. For these rea-
sons, the evaluation of NT-proBNP at the end of the first 
24 h of life appears appealing, since it could alert for 
those babies that will require more sophisticated meth-
ods to support their life such as ECMO. In fact, we hy-
pothesize that the measurement of NT-proBNP could 
separate two groups of CDH infants with different prog-
noses. In our study, plasmatic NT-proBNP  1 11,500 pg/
ml selected those CDH infants that experienced a worse 
prognosis.
 In our study, we performed an exhaustive cardiac 
function assessment by echocardiography which revealed 
significant adaptation in biventricular function, both in 
systole and diastole. The systolic RV function is impaired 
in CDH infants, probably in relation with higher RV af-
terload. In CDH infants we found an increase in LV ejec-
tion fraction, which could be related with relative under-
filling of the LV as well as with end-systolic septal bulging 
 [36] . In fact, it was previously demonstrated that the end-
systolic leftward ventricular septal shift in situations with 
RV pressure overload results in isolated augmentation of 
systolic shortening in the septal-to-free wall dimensions 
 [36] . Whereas the potential mechanisms for LV filling ab-
normalities have been pointed out above, impairment of 
RV diastolic function might be directly related with in-
creased RV afterload. In fact, afterload is a major deter-
minant of diastolic function. Severe afterload elevations 
slow down the relaxation rate and elevate diastolic filling 
pressures due to an upward shift of the end-diastolic 
pressure-volume relation  [37, 38] . Additionally, hypoxia 
and acidosis, reflected as lower Apgar indices observed in 
CDH newborns, also impair myocardial relaxation and 
might therefore further contribute to the impairment of 
both RV and LV diastolic function. The echocardio-
graphic pattern of impaired relaxation (E/A  ! 1) observed 
in both ventricles of CDH patients in the present study 
further reinforce our hypothesis. Global RV function 
evaluated by the Tei index is depressed in CDH infants. 
This finding is in line with the recent studies of Grignola 
et al.  [39] who demonstrated that the RV Tei index is a 
sensitive marker of RV dysfunction in the settings of 
acute PH.
 In the present study we documented a significant cor-
relation between NT-proBNP and estimated mean pul-
monary pressure as well as some echocardiographic indi-
ces of ventricular function (as RV Tei index and tricuspid 
E/A ratio). The increase of plasmatic NT-proBNP proba-
bly reflects ventricular adaptation to pressure overload 
secondary to PH and could be defined as a non-specific 
parameter of RV overload. Plasmatic NT-proBNP prob-
ably fluctuates according to the clinical condition of CDH 
newborns, and therapeutic management that modifies 
ventricular overload could change the level of this bio-
chemical marker. Nevertheless, it will always reflect the 
actual hemodynamic status of the infants and their re-
sponse to the treatment.
 As previously referred to by several authors, in our 
study we documented that non-survivor CDH newborns 
required more aggressive ventilation with impaired blood 
gas exchange. In fact, some parameters derived from
oxygenation status had been suggested as a potential 
marker of prognosis  [40] . The comparison of survivor 
and non-survivor CDH infants demonstrated that NT-
proBNP and estimated pulmonary mean pressure were 
significantly different in both groups, probably reflecting 
the increasing severity of the disease. Nevertheless, with 
the exception of pulmonary acceleration to ejection time 
and E/A tricuspid ratios, no other parameters of heart 
function were significantly different in both groups. We 
believe that this is due to a failure of echocardiography to 
accurately evaluate heart function and effectively differ-
entiate degrees of severity in impairment of heart dys-
function, instead of lack of increased adjustments in car-
diac function related to PH.
 In conclusion, we demonstrated that PH in CDH in-
fants induces cardiac function adaptations, which could 
be evaluated not only by echocardiography but also by 
plasmatic NT-proBNP. Although this study was carried 
out in a small number of patients, this biochemical mark-
er could be an accurate indicator of the severity of the 
clinical condition and PH in CDH newborns. Thus, it 
seems reasonable to suggest that CDH infants with early 
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elevations in NT-proBNP should alert for a subset of 
CDH infants with worse prognosis that should be consid-
ered for further study, pulmonary vasodilator therapy or 
transfer to an ECMO center.
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CHAPTER VII 
GENERAL DISCUSSION AND BIBLIOGRAPHY 
 
 
Perinatal Cardiac Function in Congenital Diaphragmatic Hernia  
 
 
In last decades the human knowledge in science and medicine has evolved 
exceedingly. In clinical practice, health indicators and gold standards improved and 
consequently, the expectation from health professionals and patients increased. 
Nevertheless, although those advances contributed to a general low perinatal 
morbidity and mortality, we still have huge challenges like CDH infants. In fact, time 
to time, despite the tremendous effort from a multidisciplinary team, we lose a CDH 
infant. Regardless the frustration behind our inability to recover these patients, there 
is a need for better understanding the mechanisms of the disease in an attempt to 
progress in therapeutics and improve the prognosis of CDH. This justifies the 
enormous efforts as well as the experimental and clinical investigation in this 
particular field. 
 
The clinical presentation of CDH infants is very heterogeneous and the outcome of 
newborns is sometimes quite surprising. At one extreme of the spectrum of the 
disease there are newborns minimally affected with excellent prognosis after surgical 
correction of the diaphragmatic defect. At the opposite, we find severe CDH cases 
with multiples associated anomalies particularly chromossomic and/or cardiac 
malformations, which determine a poor prognosis that could even result in fetal 
demise. In the middle range, we found CDH classic infants without congenital heart 
malformation, but with severe pulmonary hypoplasia and PH that require intensive 
and sophisticated treatment in addition to the straightforward surgical diaphragmatic 
correction. These newborns represent the greatest challenge for those caring CDH 
infants, because if they survive to the critical neonatal period, lung will growth 
progressively and resolution of increased vascular resistance will occur with good 
long term prognosis. This particular subset of CDH infants were the main subject of 
study of this thesis. 
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Ten years ago when our group started CDH research, the real significance of heart 
involvement was emerging [Fauza et al., 1994; Thébaud et al., 1997]. The possible 
association with congenital heart diseases and its ominous prognosis was already 
well known and pediatric cardiologist routinellly screen heart malformations by 
echocardiography. At that time, many authors revised their institutional protocols in 
order to pregnancy interruption for those fetuses with prenatal diagnosis of CDH and 
cardiac malformations. Subsequent studies analyzed the cardiac morphological 
defects associated with CDH and noticed that most of them were conotruncal 
defects, such as TOF, vascular rings, and anomalies of the aortic arch [Graziano et 
al., 2005]. Interestingly, these defects are greatly related with an abnormal neural 
crest migration which is signaled by the retinoids like vitamin A [Dickman et al., 1997; 
Niederreither et al., 2001]. After achievement of this step, clinicians stressed the role 
of congenital heart diseases in CDH and no additional information to morphological 
normality was expected from fetal or postnatal echocardiography. 
 
The close association between conotruncal cardiac malformations, lung hypoplasia 
and diaphragmatic hernia gave support to the hypothesis that retinoid signaling could 
play a major role in CDH syndrome. The retinoid hypothesis was not totally novel. In 
fact, Wilson et al. in 1953 described that vitamin A deficiency in pregnant rat females 
leads to several malformations in rat pups including diaphragmatic defects [Wilson et 
al., 1953]. More recently, several authors observed both in experimental and clinical 
studies several evidences of the association between vitamin A and CDH as well as 
lung hypoplasia [Mendelsohn et al., 1994; Thébaud et al., 1999]. Thus, the relevance 
of retinoid signaling in lung, heart and diaphragmatic development was extensively 
investigated in an attempt to find the cause of CDH and possible therapeutic targets 
[Thébaud et al., 1999; Major et al., 1998; Greer et al., 2003; Montedonico et al., 
2006]. These studies have been encouraged as several new gene mutations were 
being described involving genes for transcription of vitamin A binding proteins in 
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human CDH infants [Holder et al., 2007]. Interestingly, in the nitrofen-induced CDH 
rat model, that shares several similarities with the human disease, it was also 
established that nitrofen interferes with normal retinoid signaling [Noble et al., 2007]. 
 
It was demonstrated that supplementation with vitamin A could diminished the 
incidence of diaphragmatic defect in rat pups exposed to nitrofen, but the effect on 
heart and lung development was not entirely evaluated [Thébaud et al., 1999; Babiuk 
et al., 2004]. Aiming to contribute for this subject, we investigated what would be the 
best time for vitamin A therapy in CDH fetuses in the nitrofen-induced CDH rat 
model. In an experimental study, we confirmed that administration of vitamin A early 
in fetal development partially prevented the diaphragmatic defect and improved lung 
growth. This effect was only partial, very early in gestation, suggesting that vitamin A 
only interfere with precocious molecular mechanisms involved in lung hypoplasia 
[Baptista et al., 2005]. In our opinion, these results had clinical implications since it 
precludes the utilization of vitamin A as pharmacological therapeutics to improve lung 
growth. The fetal diagnosis of CDH in humans occurs only after 16 weeks gestation, 
when the main determinants of lung hypoplasia are mechanical. In addition, the 
utilization of vitamin A in humans at so early gestation dates involves an 
unacceptable risk of other malformations, ethically intolerable. Although this work 
does not support prenatal therapy of CDH fetuses with retinoids, it does not refute 
the hypothesis of fetal therapy based in growth factors. For instances, recent studies 
from our group found potential benefits from prenatal growth factor therapy using 
ghrelin [Henriques-Coelho et al., 2004; Santos et al. 2006] and even cytokines 
[Nogueira-Silva et al., 2006]. 
 
Regarding the heart development in the experimental vitamin A protocol, we didn’t 
found any effect of vitamin A in heart growth (non published data), despite its effect in 
lung growth. With these results we suggested that the mechanisms involved in the 
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lung hypoplasia did not affect the heart growth and reinforced our results that heart 
doesn’t present any hypoplasia at the end of gestation. Moreover, this study allowed 
us to suggest that fetal heart underdevelopment in contrast to lung hypoplasia can 
not be explained by the two-hit hypothesis.  
 
In previous works from our group, we tried to identify morphological evidence of left 
heart hypoplasia in the experimental rat model of CDH, but unexpectedly to us in an 
exhaustive study performed during gestation, in nitrofen rat model, excluding hearts 
with malformations, we only found heart hypoplasia early in gestation, with total 
normalization of heart development until term [Correia-Pinto et al., 2000; 2003]. The 
dual hit hypothesis defined that in CDH two insults occurs during lung development, 
the first one occurs early in gestation and is probably related with the molecular 
mechanisms in the origin of CDH, and the second occurs later in gestation and is 
related to the mechanical effect of abdominal organs compressing the lung [Keijzer et 
al., 2000]. On the contrary, in the nitrofen rat model the heart seems to be affect early 
in gestation, recovers during gestation, despite the mechanical effects that limit the 
parallel lung growth [Correia-Pinto et al., 2003]. Probably, the higher pressure in 
cardiac chambers precludes its compression. Curiously, more recent studies in 
humans, from several groups corroborate our findings, excluding heart hypoplasia 
and the clinical value of those echocardiographic parameters [Lin et al., 2007]. 
 
The absence of heart hypoplasia doesn’t exclude the existence of some molecular 
heart immaturity that could interfere with cardiac perinatal adaptation, causing 
hemodynamic instability in CDH infants. A few studies from one research team 
suggested cardiac molecular immaturity in CDH. These studies were performed in 
the experimental model of CDH induced by the nitrofen and demonstrated that the 
myocardium expression of several growth factors (TGFbeta, IGF-1, epidermal growth 
 106
Perinatal Cardiac Function in Congenital Diaphragmatic Hernia  
 
factor, basic fibroblast growth factor and platelet-derived growth factor) were 
decreased in CDH fetuses compared to control [Guarino et al., 2000, 2001; Teramoto 
et al., 2001, 2005]. In the nitrofen rat model of CDH induced by the nitrofen, pregnant 
female’s rats receive by gavage the teratogenic nitrofen, in a well defined time point 
of gestation (9½ dpc), causing the CDH syndrome in half of the exposed fetuses 
[Kluth et al., 1990; Tenbrinck et al., 1990]. Studies in this models requires the 
comparison not only between CDH and control pups but also between CDH and 
pups exposed to nitrofen without diaphragmatic defect (the nitrofen group). 
Nevertheless, in the published studies suggesting heart immaturity in CDH, the CDH 
pups were only compared to control groups with evident under-expression of defined 
growth factors. The absence of comparison of CDH group with nitrofen group could 
represent a significant limitation of these studies, since the observed 
underdevelopment could be related only with the effect of nitrofen, and not with real 
immaturity associated with CDH. On the other hand, those studies had been carried 
out only in fetuses at term. For those reasons we decided to further investigate the 
presence of molecular heart immaturity in CDH.  
 
Heart development evolves with alterations in cardiomyocyte-specific gene 
expression. These adaptations occur at different levels either at cell-to-cell 
communication as well as at intracellular calcium kinetics and contractile proteins 
[Chen et al., 2000; Kaba et al., 2001; Reiser et al., 2001]. We performed a study 
evaluating, in the nitrofen-induced CDH rat model, gene expression of cardiac 
molecular parameters that are developmentally regulated and reflect each of those 
levels of adaptations: i) connexin 43 mRNA, to cell-to-cell communication; ii) 
SERCA2A mRNA, to intracellular calcium kinetics; iii) myosin heavy chain protein 
isoforms, to contractile proteins. We didn’t found any molecular signs of myocardium 
immaturity in this experimental model of CDH, since the molecular parameters were 
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similar in all studied groups (control, nitrofen and CDH groups) [Baptista et al., 2006]. 
With these results, we exclude the hypothesis that heart hypoplasia or immature 
could be the missing link in CDH responsible for greater mortality. Nevertheless, in 
our clinical practice we progressively recognize that CDH newborns present acute 
heart failure. Since heart hypoplasia and underdevelopment were excluded, we 
realize that this might be caused mainly by cardiac overload secondary to severe PH.  
 
Pulmonary vascular abnormalities in CDH are described by several authors [Geggel 
et al., 1985; Beals et al., 1992; Roubliova et al., 2004; Taira et al., 1998]. In CDH 
human fetuses, the pulmonary vascular tree demonstrates a developmental arrest of 
arterial branching at 12–14 weeks’ gestation. The diameter of the vessels is 
decreased in relation to lung volume. This results in a decreased cross-sectional 
area of the vascular bed, with increase in pulmonary vascular resistance. In some 
infants, intraacinar arteries have a muscular wall, whereas other infants have no 
distal muscularization. Muscular wall thickness and muscle mass are increased in 
arteries bilaterally, compared to normal controls, and this increase in muscle mass is 
inversely proportional to the degree of lung hypoplasia. 
 
Vascular anomaly that occurs during fetal development in CDH causes severe PH in 
affected newborns which has been proposed as one of the main determinants of 
mortality [Dillon et al., 2004]. Pulmonary hypertension, beside interfere with gas 
exchange, causes right-to-left shunt at foramen ovale and ductus arteriosus, inducing 
hypoxia and acidosis which in turn aggravate pulmonary vascular constriction 
[Correia-Pinto, 2003]. In these patients, cardiac performance could be hampered due 
to increased RV afterload and impaired myocardial tissue oxygenation, which could 
be responsible for additional morbidity. It is well known that PH from other etiologies, 
in children and adults, causes RV adaptation, with hypertrophy and dilatation, that 
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progress to heart failure. Additionally, several studies suggest that in PH the LV also 
suffers both systolic and diastolic function adaptation, due to bulging of ventricular 
septum and reduced RV output [Louie et al., 1995]. Nevertheless, the significance of 
pulmonary vascular anomalies and PH in heart function during perinatal development 
in CDH was not considered until recently. Thus, when we started assessment of 
heart function in CDH, two key questions were in our mind: i) do pulmonary vascular 
anomalies causes any repercussion in heart function during prenatal development? 
ii) what is the impact of PH in heart function after birth?  
 
There are very limited data regarding fetal pulmonary vascular function in lung 
hypoplasia. In one limited study it was demonstrated in two fetuses with CDH and 
autopsy-proven pulmonary hypoplasia, that pulsatility index in the branch PA was 
elevated in utero [Chaoui et al., 1999]. A subsequent study, evaluating reactivity of 
the pulmonary vasculature in response to maternal hyperoxygenation, demonstrated 
a higher mortality in fetuses with a non-reactive test and lung hypoplasia [Broth et al., 
2002]. Despite those, the impact of pulmonary vascular hypoplasia and increased 
vascular resistance in heart function during prenatal heart development was largely 
unknown. 
 
The evaluation of heart function in experimental animal models is complex and not 
easily assessed by ultrasonography. Assessment of several biochemical markers of 
ventricular overload in the experimental model of CDH might provide an acceptable 
alternative to echocardiography. Several biochemical and genetic markers have been 
suggested to evaluate ventricular load and function, both in animal models and 
humans, like BNP, components of renin-angiotensin system and ET-1 [Miyauchi et 
al., 1993; Lorrel, 1995; Nagaya et al., 2000; Aubert, 2005]. The genetic expression of 
those proteins in fetal heart from early stages of development was already 
demonstrated [Beinlich at al., 1993; Cameron et al., 1996; Brand et al., 2003], but its 
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cardiac expression during late stages of pregnancy is far from being clear, even in 
normal fetuses. In the experimental nitrofen rat model of CDH we determined the 
cardiac expression of BNP, angiotensiogen and ET-1 mRNA during perinatal 
development in normal and nitrofen-exposed rats [Baptista et al., in press]. 
 
In control rat fetuses, cardiac expression of these genes showed temporal changes, 
suggesting a closely regulated developmental expression. Interestingly, we found a 
ventricular mirror-image expression of angiotensinogen and BNP: when BNP mRNA 
increases, angiotensinogen mRNA decreases. The opposed effect of natriuretic 
peptides and angiotensin in myocardium as well as in vessels is well known. 
Generally, BNP have potent inhibitory effects on the renin–angiotensin–aldosterone 
system [Burger et al., 2005] and, in heart failure, activation of the renin–angiotensin–
aldosterone system is suppressed by BNP [Takahashi et al., 2003]. These systems 
might form an important regulatory complex of fetal vascular physiology and 
development. Hypothetically upheaval in that delicate control network could interfere 
in the cardiopulmonary hemodynamic and lead to disease. 
 
Regarding nitrofen-exposed fetuses, our results showed late fetal cardiovascular 
molecular changes that were probably related with nitrofen. In fact, during fetal life 
we didn´t found any difference in genic expression of BNP, angitensinogen or ET-1 
between CDH and nitrofen groups, excluding the hypothesis of fetal heart 
adaptations linked to CDH. Remarkably, the pattern of opposed direction of 
expression of BNP and angiotensinogen, observed in control rat fetuses, is 
preserved in nitrofen exposed fetuses. On the contrary to fetal results, we found RV 
molecular adaptation to pressure overload in CDH pups after birth, with increased 
myocardial expression of all studied genes compared to prenatal expression and 
compared to both control and nitrofen groups. This response was specific for RV and 
in this model we did not demonstrate any LV molecular adaptation to PH immediately 
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after birth. Our experimental study demonstrated that PH cause neonatal heart 
molecular adaptation, but the presence of heart dysfunction was still unrevealed.     
 
The relevance of identify heart failure in human CDH infants is of utmost importance. 
Besides better understanding of the disease mechanisms it could have some clinical 
impact in the handling of the affected patients. Additionally, if heart function is 
partially dependent of pulmonary pressure, the evaluation of heart function could 
predict the severity of PH. In the absence of effective treatment of lung hypoplasia, 
the post natal manipulation of pulmonary vascular resistance is the foremost 
objective in CDH management. In this regard, PAP assessment is crucial to decide 
upon pulmonary vasodilator therapy as well as to monitor its effects. This 
requirement implies that the quantification of PAP and the assessment of heart 
function should be done using exact parameters, generally using echocardiography. 
However, several aspects should be considered in relation with echocardiography, 
namely in PAP estimation and heart function evaluation in newborns. 
 
In experienced hands, echocardiography is a safe and adequate method to evaluate 
heart anatomy and function. Nevertheless, it is somewhat observer-dependent and 
technically demanding in CDH infants, due to mechanical ventilation and the 
presence of abdominal organs in thoracic cavity. Considering PAP estimation, it is 
based on tricuspid regurgitation using Doppler echocardiography and it is essential 
an exact alignment of the Doppler sample to achieve the greater gradient between 
RV and atrium. In CDH patients, the distortion of the heart frequently difficult the 
correct sample alignment with gross errors in estimated PAP. Additionally, the 
presence of TR is not universal in all patients with PH, and usually doesn’t exist in 
healthy individuals. For all this reasons, in our studies we evaluated both the 
estimated pulmonary systolic pressure and also the estimated mean pulmonary 
pressure, based on acceleration time of pulmonary flow. The evaluation of PH was 
 111
Maria João Ribeiro Leite Baptista 2007 
 
also complemented with indirect signs, like shunt direction at foramen ovale and 
ductus arteriosus, the bulging of interventricular septum, as well as RV dilatation. 
Regarding evaluation of heart function with conventional echocardiography it is very 
challenge the assessment of RV due to its geometrical characteristics. Additionally, 
several heart function parameters defined in adults are uncertain in newborns due to 
normal heart function adaptation that occurs after birth. In fact, transition to post-natal 
life is accomplished by vascular and pulmonary adaptations, with particular load 
conditions that could interfere in evaluated parameters. In our clinical study, to 
evaluate heart function we selected echocardiographic parameters previously 
defined [Kinsella et al., 1992; Sugiura et al., 2004]. Right ventricle was evaluated with 
pulmonary acceleration time-to-ejection time (for systolic function), E-to-A ratio on 
tricuspid valve (for diastolic function) and RV Tei index (for global function). Left 
ventricle was evaluated with LV ejection fraction (for systolic function), E-to-A ratio on 
mitral valve (for diastolic function) and LV Tei index (for global function) [Tei et al., 
1997]. Despite this echocardiographic assessment, due to all previously explained 
limitation, easy and reliable methods to assess PH and its impact in cardiac function, 
in addition to conventional echocardiography, are required.  
 
Several recent studies have demonstrated the clinical relevance of biochemical 
markers to evaluate and determine the prognosis in patients with heart failure and 
PH [Nagaya et al., 2000; Bettencourt, 2004; McLaughlin et al., 2004]. Several 
molecules which can be measured in the blood or sometimes in other biological fluids 
are known to be elevated in PH [Voelkel et al., 2000; Torbicki et al., 2003; Aubert, 
2005; Abdul-Salam et al., 2006]. From several biochemical markers (uric acid, 
troponins), NT-proBNP is considered the most useful biochemical marker of 
ventricular overload in addition to echocardiography in adults. At the beginning of our 
studies, little information was available about NT-proBNP in infants. In a small group 
of newborns with critical pulmonary stenosis or atresia, submitted to cardiac 
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therapeutic catheterization we found a significant positive correlation between 
plasmatic NT-proBNP and RV systolic pressure [Baptista et al., 2005]. In the 
meantime, several authors demonstrated the significance of NT-proBNP in 
ventricular overload in infants and children [Reynolds et al., 2004; Nir et al., 2004]. 
 
In an extensive clinical study we evaluated during two years every CDH infants 
admitted to our center. We assessed 18 CDH infants, at 24 hours of age. This time 
point was decided because during the first day of life these babies usually present 
hemodynamic and respiratory stability, the honeymoon period, and only after that 
stage the significance of PH could be ascertain. In selected infants, heart function 
was evaluated with several echocardiographic parameters of ventricular systolic and 
diastolic function. In those patients, plasmatic NT-proBNP was measured at the 
same time point. The results were compared to an age-matched healthy group, 
needing blood collection for other reasons. The results from our clinical study 
revealed that CDH infants presented ecocardiographic and biochemical evidence of 
heart dysfunction in relation with severity of PH. The echocardiographic assessment 
revealed that heart adaptation occurs in systolic and diastolic function of both 
ventricles, but mainly in RV. Interestingly, we found significant differences between 
CDH and control infants in echocardiographic parameters but no difference was 
found between CDH survivors and non-survivors. Regarding biochemical markers we 
found a significant increased of NT-proBNP in CDH infants in comparison to control 
newborns, but this difference is enlarged when we compare CDH survivors and non-
survivors. In fact, NT-proBNP significantly correlates with estimated pulmonary 
pressure but doesn’t have correlation with measured echocardiographic parameters 
of heart function. We found an excellent correlation between NT-proBNP and echo 
parameters of heart function in CDH survivors and control groups, but this correlation 
is absolutely loosed in CDH non-survivors group [non published data]. Plasmatic NT-
proBNP seems to be more effective than echo parameters of heart function to 
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evaluate the hemodynamic impact of PH. We believe that plasmatic NT-proBNP 
should be added to echo parameters to assess heart function in order to closely 
follow up PH and its repercussion in heart function.  
 
Thus, in the sequence of our work we suggest one protocol the evaluate PH and 
heart function in CDH newborns, in a simple and feasible way. This protocol should 
be followed in a multidisciplinary approach in order to improve PH assessment and 
manipulation. 
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Clinical protocol to cardiac assessment in CDH 
 
1. Fetal assessment  
a. 20 weeks gestation (or as soon as diagnosis of CDH) 
i. Screening of congenital heart malformation 
1. Cono-truncal anomalies 
2. Associated anomalies (e.g., minor VSD) 
ii. Evaluation of heart hypoplasia (interest not yet established)  
iii. Heart and vascular function (not established) 
1. Pulmonary pulsatility index 
b. Serial evaluation until term 
2. Neonatal assessment  
a. First day of life 
i. ECHO 
1. Screening of congenital heart malformation 
2. Pulmonary pressure estimation 
a. Pulmonary artery systolic pressure (PASP) 
b. Pulmonary artery mean pressure (PAMP) 
b. Second day of life (around 24 hours) 
i. Biochemical 
1. NT-proBNP 
2. Uric acid (not established) 
3. Troponin T (not established) 
ii. ECHO 
1. Pulmonary artery pressure quantification  
a. Estimation of PASP and PAMP 
b. Shunt direction at foramen ovale and ductus 
arteriosus  
c. Interventricular septum direction 
d. RV dilation (tricuspid-to-mitral ratio) 
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2. Heart function 
a. Right ventricle 
i. RV acceleration time/ejection time 
ii. E/A wave ratio  
iii. Tei index 
b. Left ventricle 
i. Ejection fraction 
ii. E/A wave ratio 
iii. Tei index 
c. Repeat BIOCHEMICAL and ECHO (same as day 2): 
i. Clinical deterioration/follow-up (dependent of clinical status) 
ii. Day before surgery and day after 
iii. Before discharge 
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Regarding fetal echocardiographic evaluation on CDH fetuses, we believe that 
identification of heart malformations should be the main objective. Suggested 
parameters of prognostic, like LV hypoplasia, are very demanding, not consensual 
and without benefit in comparison to recently defined parameters like lung-to-head 
ratio or lung dimensions achieved by fetal resonance.  
 
After birth, the pediatric cardiologist might be strongly committed in management of 
CDH patients. In the first hours of life, echocardiography should be performed to 
assess the presence of congenital heart disease but even in the absence of heart 
malformation the pediatric cardiologist should be part of the multidisciplinary team 
and participate in clinical decisions. Pulmonary pressure could be estimated by 
echocardiography at this time, but generally CDH infants have normal to slightly 
elevated pulmonary pressure in the first 24 hours of life.  
 
The crucial cardiac assessment of CDH infants should be done at 24 hours of life, 
with plasmatic NT-proBNP measurement and echocardiography. NT-proBNP seems 
to have prognostic interest, and levels higher than 11 500 pg/ml is suggestive of 
worse prognosis and poor survival. Echocardiography should include pulmonary 
pressure estimation and evaluation of indirect signs of PH severity (ventricular 
septum and shunt direction). Echocardiographic evaluation should also include 
parameters of systolic and diastolic bi-ventricular function. If possible, it should be 
performed by the same observer, in order to exclude inter-observer variation. 
 
The assessment of plasmatic NT-proBNP as well as echocardiographic estimation of 
pulmonary pressure and heart function might be repeated in case of clinical 
instability, before and after surgery, and at discharge. Patients with persistent high 
pulmonary pressure at discharge should be referred to a pediatric cardiology 
consultation.  
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Plasmatic NT-proBNP is more useful when evaluated repeatedly and compared to 
previous results. It is a very sensitive marker, and frequently we found significant 
increases before clinical deterioration occurs. Other biochemical markers of PH are 
not proved to be useful in newborns and should not be employed to adjust 
therapeutics. 
 
Future Directions 
 
At this time several question remains to be defined and would be the key of our 
future investigation in CDH. 
1. We are assessing the clinical expression of several biochemical markers, 
defined mainly in adults with PH, like uric acid, troponins and ADMA, in 
order to evaluate its helpfulness as prognostic parameters and 
monitorization of PH and heart dysfunction. 
2.  We will investigate the relevance of tissue Doppler in CDH infants, since 
tissue Doppler is a remarkably method of evaluation of pulmonary pressure 
and heart function, independent of load conditions. 
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